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Pool ROUTINE PROPHYLACTIC PEG
FEEDING PERMITS MORE EFFECTIVE
RADICAL CHEMO-RADIOTHERAPY IN
HEAD AND NECK CANCER.
H.A. Payne, R.S.D. Brown, G.M. Blackman, G. Spencer and J.S.
Tobias, Meyerstein Institute ofOncology, Middlesex Hospital,
London, WIN 8AA.
A retrospective analysis of 38 patients undergoing radical
radiotherapy for head and neck cancer (predominantly advanced
oral or oropharyngeal carcinoma) compared our current practice of
prophylactic Percutaneous Endoscopic Gastrostomy ("PEG")
insertion for nutritional support with a group ofhistorical controls.
Results patients with prophylactic PEG missed no treatment due
to radiation-induced morbidity whereas controls missed an average
of 1.83 days. Mean weight change in prophylactic PEG patients
also differed significantly , with an increase of 0.64 kg compared
with a mean weight loss of 5.5 kg for the control group. Serum
albumin increased on average by 2 g/dl in PEG patients but fell on
average by 3 g/dl in control patients.
33 % ofcontrol group patients required insertion ofgastrostomies
during radiotherapy because ofinadequate ongoing nutrition.
In view of increasingly convincing published evidence for the
detrimental effect on tumour control from treatment delays,
together with prolonged or delayed healing of radiation reactions
from poor nutritional status, we now recommend PEG insertion as
an essential and routine part of the radical management of locally
advanced oral / oropharyngeal carcinoma.
P003 IMMUNOHISTOCHEMICAL STUDY OF EXPRESSION OF
HEAT-SHOCK PROTEIN 27 (HSP27) IN NORMAL AND
MALIGNANT ENDOMETRIUM, 0. Devajal, R. Nathl, R.J.B.
King 2, K.S. Raju 1. Dept. of Obs. & Gynae. U.M.D.S. St. Thomas' Hospital,
London SI1 7EH, 2 School ofBiological Sciences,University of Surrey, Guildford.
A HSP27 synonymous with p24 and p29 has been implicated in
oestrogen action but its role in the oestrogen receptor (ER) machinery is
not fully understood. It has been shown that HSP27 is predominatly
expressed in cytoplasm within the perinuclear region near golgi complex
in oestrogen reactive tissue like breast, fallopian tubes and even skin.
Apart from its role in the ER function HSP27 is involved in wide range
of biological activites ranging from embriogenesis, cytokine effect,
growth stimulation of some epithelial cells, drug resistance and
tumorogenesis.
The aim ofthis study is to asses expression of HSP27 in different
cells in the normal postmenopausal and premenopausal endometrium and
its presence in different grades ofendometrial carcinoma.
Specimen of endometrium (both benign and malignant) were
collected during 1995/96 from patients operated in St. Thomas' Hospital
London. The specimens were formalin fixid and routinely processed in
pathology department. All slides were stained with D5 antibody specific
for HSP27 using previosly described method by Cano et al. Intensity of
staining was assesed using our own scoring system and divided into
four group:1) no staining 2) mild 3) moderate 4) strong. A total of 80
patients were studied and divided into three groups:1) pre-menopausal
women with normal menstrual cycle n=30 2) postmenopausal women
n=20 3) women with atypical hyperplasia and endometrial cancer n=30.
Staining was strongly positive in endometrial glandular epithelium
only in the middle ofthe cycle. The number ofpositive cells and intensity
of staining decreased from early secretory towards the late secretory
phase in glandularepithelium and stromal cells become first time positive
in late secretory phase. Post menopausal endometrium and stroma were
negative. In atypical and malignant endometrium there was clear
relationship between histological grade oftumor and HSP27 expression.
All three specimens with atypical hyperplasia were strongly positive for
HSP27. Seven out of eight well differentiated cancers were moderately
to strongly positive but only four out of nine moderately differentiated
cancers stained positive. None of ten poorly differentiated cancers
showed staining for HSP27. Findings in malignant endometrium suggest
that HSP27 may be an excellent marker oftumourdifferentiation.
P002 OBJECTIVE RESPONSE TO CHEMOTHERAPY
AND SYMPTOM CONTROL IN RECURRENT
HEAD & NECK CANCER. M.E. Hill D Constenla,
R.P. A'Hem, J.M. Henk, P. Rhys-Evans, N. Breach, D. Archer' M.E. Gore.
The Head and Neck Unit, Royal Marsden NHS Trust, London,SW3 6JJ.
Background: Squamous cell carcinoma of the head and neck (SCCHN) is
chemosensitive in the neoadjuvant setting, but response rates are relatively
low at relapse after surgery +/- radiotherapy. The rationale for
chemotherapy in recurrent disease is that objective response (OR) should
correlate with reduction in symptoms, as has been demonstrated in other
solid tumours. In prior studies of chemotherapy in SCCHN however,
symptom control has rarely been adequately reported or related to OR. We
therefore set out to do so using our prospectively accrued database of
patients undergoing palliative chemotherapy for recurrent SCCHN.
Methods: Best symptom response (SR) was recorded after each course of
chemotherapy using a published 3-point scoring scale (Hardy et al, Br J
Cancer 60:764, 1989). Maximum OR was measured by standard WHO
criteria after alternate courses.
Results: 57 patients were identified who had received chemotherapy, mainly
cisplatin/5-FU combinations. Of the 52 patients evaluable for OR, there
were 4 CRs and 14 PRs (response rate 35%/o). All patients had at least one
symptom with a total of 103 symptoms recorded. Overall 43% ofsymptoms
improved, 50% were unchanged and 7% worsened during chemotherapy.
The number of patients with improvement in the most commonly reported
symptoms were as follows: pain 11/28 (39%), swelling 12/23 (52%) and
dysphagia 6/18 (33%). 67% of patients with OR also had SR, but a
significant proportion of patients (33%) who did not have an objective
response to chemotherapy described improvement in symptoms. Lack ofOR
was not correlated with deterioration in symptoms. Grade 3/4 toxicity was
uncommon (6-17%) and there were no toxic deaths. The vast majority
(82%) of patients experienced either no change or an improvement in
performance status.
Conclusion: Chemotherapy for recurrent SCCHN has useful palliative
benefits for many patients. Symptomatic improvement is more likely ifthere
is evidence of significant tumour shrinkage, but even non-responding
patients can benefit.
P004
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P005 PLACENTALSITETROPHOBLASTIC
TUMOUR (PSTT): RARE BUT
POTENTIALLY CURABLE.
A MGillespiel, D Liyiml, J Goepel2, RE Coleman,' B W Hancock'.
'YCRC Dept. of Clinical Oncology, Weston Park Hospital, Sheffield,
2Dept. of Pathology, Royal Hallamshire Hospital, Sheffield.
PSTT is a rare form of Gestational Trophoblastic Disease (GTD). Less
than 100 cases have been reported since it was first described in 1976.
PSTT consists largely of cells from the intermediate tropoblast which
produce human Placental Lactogen (hPL) as opposed to human
Chorionic Gondatrophin (hCG). Arising from any form of antecedent
pregnancy, PSTT is more is more commonly associated with adverse
outcomes than other forms of GTD. We have conducted a rettpspective
analysis of all cases of PSTT managed at the Sheffield GTD Centre
since 1984, and now report our findings in a series of 7 previously
unpublished cases. The median age was 37 years (range 26-54). In 5/7
cases the antecedent pregnancy was a live female conception, 1/7 a live
male and in the other case the patient reported no previous pregnancies.
The time delay between antecedent pregnancy and presentation with
PSTT was varied (range 14 months - 13 years), the most common
presenting symptoms being irregular vaginal bleeding +/- a period of
amenorrhoea. The median hCG at diagnosis was 107 ui/L (range 6-
107,600). 3/7 cases had disease confined to the uterus and were treated
successfully by hysterectomy alone. 2 patients in addition to uterine
tumour, had pulmonary metastases. Both patients were treated with
combination chemotherapy (cisplatin/etoposide/cyclophosphamide) and
are alive and well with no evidence of disease 3 and 6 years after
treatment respectively. The remaining 2 patients had widespread
metastases and both died despite numerous surgical, chemotherapeutic
and radiotherapeutic interventions. In conclusion PSTT commonly
presented following a live female antecedent pregnancy after a
significant time delay; those patients with disease confined to the uterus
or with lung metastases only, had a successful outcome.
P007 GENE THERAPY FOR OVARIAN CARCINOMA USING
E.COLI NITROREDUCTASE AND CB1954 R.G. Barton
I.A. McNeishl, M.G. Gilliganl, D.J. Kerr1, MJ. Ford2,
C.J. Springer3 and P.F. Searlel 1CRC Institute for Cancer Studies, University of
Birmingham, B15 2TA. 2Glaxo-Wellcome Research and Development, Stevenage,
SG I 2NY. 3Institute for Cancer Research, Sutton, Surrey,SM2 5NG.
The E.coli enzyme nitroreductase (ntr) converts the weak,
monofunctional alkylating agent CB1954 (5-(aziridin-1-yl)-2,4-
dinitrobenzamide), into a highly active bifunctional metabolite which is
toxic to both cycling and non-cycling cells. The human ovarian carcinoma
cell line SKOV3 was transduced with the recombinant retrovirus LNC-ntr
with titres of 1 -5 x 105 cfu/ml. With a multiplicity of infection ofjust 1
cfu/cell and transduction efficiency of -20%, the sensitivity to CB1954 of
unselected, transduced populations increased by a factor of 10 relative to
nontransduced parental cells. By selection with G418, clones were
obtained that were up to 200 times more sensitive to CB 1954 and
Western blotting demonstrated a direct correlation between level of ntr
expression and sensitivity to CB1954. Alternative contructs with 259 bp
deleted from the 3' end of the ntr gene, removing the bacterial tenrination
sequnces, resulted in significantly higher ntr expression and G418
selected clones were all at least 1000 times more sensitive to CB1954. A
shortened ntr construct has been transduced into the novel producer cell
line, FLY, and a high titre clone selected. Using the resultant retrovirus,
FLY RD18 nr, unselected, transduced populations of SKOV3, IGROVI
and Cisplatin resistant A2780-CP cells were sensitised tenfold to
CB1954.
Cell mixing experiments using a highly sensitive SKOV3 clone
demonstrated that, at high plating density, with only 5 % ofcells within a
mixture expressing ntr, the whole population was 10 times more sensitive
to CB1954 than parental cells. If 30% of the cells expressed ntr, the LDI0
for the whole population was the same as that for 100 % ntr positive
cells.
These data show that transient exposure of tumour cells to retrovirus
carrying the gene encoding nitroreductase renders them sensitive to
CB1954 and that the ntr/CB1954 enzyme/prodrug system is a valid
candidate for virus directed enzymeprodrug therapy.
P006 HPV-16 E5 INDUCED LYMPHOCYTE RESPONSES IN CERVICAL NEOPLASIA. C Biswas', DKGill3, KS Rajul, JM Best2,
NA Punchard3 &J Cason2. Depts of 'Gynaecology and2Virology,
UMDS, St Thomas' Campus, London SEI 7EH and3Faculty ofScience, University of Luton, Park
Square Luton LUI 3JU.
Introduction E5 is a weak oncogene of human papillomavirus type 16
(HPV-16), the major aetiological agent in cervical intraepithelial
neoplasia (CIN) and cervical cancer. T-cell proliferation and antibody
responses to synthetic HPV-16 E5 were investigated in 48 women with
CIN and 20 normal controls, in order to determine whether these
responses are related to disease status and the presence of HPV-16
DNA.
Method Peripheral mononuclear cells from each patient were
stimulated with synthetic E5 and stimulation indexes (SI) determined.
Patients' sera was tested for E5 antibodies by enzyme immunoassay.
Cervical cells were analysed for the presence of HPV-16 DNA by
polymerase chain reaction.
Results Patients with high grade CIN lesions produced lower SI values
in response to HPV-16 E5 than normal controls or those with low
grade CIN. Only 20% of women poEitive for HPV-16 DNA responded
to in vitro stimulation. Weak antibody responses were present in all
groups ofpatients but were highest for those with CINII.
Conclusion Reduced T-cell responses to HPV-16 E5 maybe important
in the pathogenesis of CIN. Concurrent HPV-16 infection appears to
have a down-regulatory effect on E5 specific T-cell proliferation.
These findings may have implications in the development of a vaccine
against cervical cancer and will be investigated further.
P008
Luteinising Hormone (LH) and Follicle Stimulating Hormone (FSH)
are growth factors for Endometrial Cancer Cell Line HEC-1A.
Davies S, Bax CMR, Chatzaki E, Gallagher CJ. Medical Oncology St
Bartholomew's Hospital London ECIA 7BB
We examined the effect ofLH and FSH on endometrial cancer cell
line growth to see whether suppression ofLH and FSH by
gonadotrophin releasing hormone analogues could explain their ability
to cause tumour regression in up to 25% ofpatients and yet have no
direct receptor mediated effect in vitro (Chatzaki et al Cancer Res
1996; 56: 2059) Both LH and FSH act via cAMP linked membrane
receptors for which we were able to establish a bioassay using
HEK293 cells stably transfected for LH receptor (293L cells) or FSH
receptor (293 F cells) (D. Seagloft Iowa USA) and a radioimmuno
assay (Amersham) for cAMP. The dose(10-1000 iu/L) dependant
response is blocked by the appropriate anti-LH or anti-FSH
monoclonal antibodies (Harlan-Sera Lab) in 10 fold molar excess.
Serum free cell growth was measured in triplicate using a
densitometric DNA assay and expressed as % ofcontrol cell growth.
Addition ofpituitary extracted LH or FSH (Sigma) resulted in a non-
specific increase inHEC-1A cell growth. Recombinant human LH and
FSH (Serono Lab) which showed potent cAMP stimulation above 100
iu/L stimulated HEC- 1A cells in dose dependant manner with a
maximum increase of 160% at 300 iu/L rhLH equivalent to the
maximal response seen to 10% FCS or the sigma LH 1000 iu/L.
Similarly rhFSH and simulated HEC-lA growth with a maximum
increase of 150% at 1000 iu/L in comparison with 175% response to
10% FCS and 200% with Sigma FSH 1000 iu/L. However there was
no stimulation ofcAMP production in the HEC 1-A cells. We are
examining whether LH and FSH may be acting by two different paths
to promote secretion via cAMP and cell growth via inositol phosphate
linked second messengers in endometrial cancer.Poster Presentations 41
P009 CANPACL1TAXEL BEDELIVEREDBY
CONTINUOUSAMBULATORY INFUSION? RK
Gregory,PMainwaring, MHill,LPyle,MARamsden MEGore. Royal
MarsdenHospital,London.
InvitrosXdeshavedenonstratedtathecytotoxcityofpaclitaxel isenhancedby
incasedd dugexposure. Itmaythereforeberationaltodeliverpacitaxelby
continuous intravenous infusionThereareanumberofproblems withsuchan
apptoh,notthe leastofwhichisthepoorsolubility ofpaclitaxel.Nevertheless
we decidedto explorethe feasibility ofthis schedule ofadministration.
Methods: ThestudywasdesignedasaphaseItrial, 15patientswithrelapsedor
reftorycarcinomaoftheovary wereenrolled,6atdoselevelI(130mg/m2); 3
atdose levelIl (170mg/m2); 3 atdose level ml(220mg/m2)and3 atdoselevelIV
(290mg/m2). Thedrugwasdelveredcontinuously over6weeksonan 8week
cycleviaaHickman line. Duetotheinstability ofpaclitaxelthepatientswere
requiredtoattendthehospitalthreetimesaweekfortheirinfisionresevoirstobe
changed.
Resuls: Patientstoleatedtheteatmn textrmnely well, toxictywasminimal; the
mainproblemenco teredwasprecipitationofthe druginthe infusionline.This
resulted inachange ofpolicy so thatthereservoirs hadtobechangeddaily.4/15
patients completedthe iniial6weeksoftreatnentjI patientacheived stabledisease
after 8 months 3 hadpmgrssive disease (2after2 monthsand lafter3months).
Theremaining 11patientsdevelopedprogrssivediseasewithinthefist6weeks
oftreatnent.
Discusion: Wehaveshownthatcontinuous infiusionofpacitaxelisfeasibleand
welltoleratedbypatientsbutthereservoirsrequiredchangingdailyandthisisvery
inconvenientand impatical forthemajonityofpatients.Thepoorresonserate
could inpartbeaccountedforbythelowdose intensitydelivered, noneofthe
patients receivedadoseintensityequivalentto 175mg/m2over21 days.
POl1 USE OF THE DELTA ASSAY OF PLASTIC ADHERENT PROGENITORS (PA) TO MEASURE
EARLY HAEMOPOIETIC PRECURSORS IN
PERIPHERAL BLOOD HARVESTS
J. Adams', D. Clarke', M. Gesinde2, A. Lubenko2, G. Morgan3, T.J.
Perren', P.J. Selby', P.W.M. Johnson'.
'ICRF Cancer Medicine Research Unit, St James' s Hospital, 2National
Blood Service, 3Centre for Haematological Oncology, Leeds, UK
Purpse: To determine the relationship between plastic adherent early
stem cell progenitors and engraftment following peripheral blood
progenitor cell (PBPC) rescue.
Methods: 30 patients (pts) undergoing high dose chemotherapy and
PBPC rescue were studied for the relationship of harvest CD34+ cell
count, granulocyte-macrophage colony forming units (CFU-GM) and
plastic adherent progenitor-derived CFU-GM to platelet and
neutrophil recovery times. Patients were treated in remission from
multiple myeloma (9), breast cancer (10), lymphoma (8) and teratoma
(3). Mobilization was with G-CSF 4-8 pg/kg/day during recovery
from induction chemotherapy. Harvests were analysed for CD34+
cell count by flow cytometry. Apheresis products on the first day were
tested in CFU-GM and a delta assay (PA) performed with the progeny
from the plastic-adherent fraction of 107 mononuclear cells incubated
for7 days and enumerated by CFU-GM assay.
Results: A median 3.69x106 CD34+ cells/kg were reinfused (range
0.25-51.9), 6.1x104 CFU-GM/kg (range 0.10-79.0) and 10.4x104 pA
CFU-GM/kg (range 0.27-603.8). Median time to platelet count of
50x109/l was 14 days (range 9->80) and to neutrophil count of
0.5x109/l was 13 days (range 9-27). Inverse correlation was seen
between the CD34+ count of reinfused cells and time to recovery of
platelets (p=0.002) and neutrophils (p=0.005). Correlation was also
seen between CFU-GM and platelet recovery (p=0.031) but not
neutrophil recovery. There was positive correlation between CD34+
count and PA CFU-GM numbers (p=0.037) but no correlation was
seen between PA CFU-GM count and engraftment time.
Conclusion: The delta assay of plastic adherent progenitor cells is
capable of quantitating a primitive population in PBPC harvests but
the CD34+ cell count remains superior as a means of predicting
engraftment, suggesting that committed progenitors are more
influential in the early phase of recovery.
Polo MAGNETIC RESONANCE IMAGING OF THE WHOLE
SPINE IN SUSPECTED SPINAL CORD
COMPRESSION: IMPACT ON MANAGEMENT.
AM Cookl, ATN Lau2, MJ Tomlinson1, M Vaidya2, CJ Wakeley2 and P Goddard2.
I Bristol Oncology Centre, 2 Department of Clinical Radiology, Bristol Royal Infirmary.
OBJECT :To assess how often patients with suspected cord
compression present with a misleading sensory level or have
multiple levels of compression, not apparent clinically and to
evaluate a policy of Magnetic Resonance Imaging (MRI) of the
whole spine for any case of suspected cord compression.
METHOD: MRI scans and hospital notes of 127 patients who had
had 133 MRI scans of the whole spine between January 1993
and December 1995 were reviewed.
RESULTS: In 90 of 133 scans evidence of cord compression or
impingement was found. A sensory level was present in 52 ofthe
90 patients but in 13/52 (25%) the sensory level was four or more
segments below or three or more segments above the actual
lesion. Multiple levels ofcompression or impingement were found
in 37 of 90 (41%) patients, 28 of 37 involving more than one
region ofthe cord. Of 32 patients who commenced radiotherapy
to a treatment volume based on clinical criteria before the MRI
scan was available, the radiotherapy fields needed modification
in 16(50%) as a result ofthe MRI findings.
CONCLUSIONS: The results support a policy of MRI of the
whole spine in any case of suspected cord compression, whether
or not there is a clinically suspicious site.
P012 EFFECT OF AUDIT ON PRESCRIPTION OF
RADIOTHERAPY FOR BRAIN METASTASES
G E Gerrard, Dr M Bottomley, H M Murphy
Yorkshire Centre for Cancer Treatment, Cookridge
Hospital, Leeds.
Introduction The recently published Royal College of Radiologists Trial comparing 2
different fractionation schedules in the treatment of cerebral metastases concluded that 2
fractions can be as effective as 10 for the majority of patients. A reduction in the number of
fractions will reduce treatment machine and radiographer workload and reduce the
inconvenience to the patient. We investigated the effect ofaudit on prescribing practices at this
centre.
Methods For 3 months prior to the audit meeting all patients treated with palliative
radiotherapy for brain metastasis were audited. This data and the trial results were presented
at an audit meeting and a departmental policy was created. Subsequently a memorandum was
circulated recommending 12 Gy in 2 fractions on consecutive days for the majority ofpatients
and 20 Gy in 5 fractions over 7 days or 30 Gy in 10 fractions over 14 days for a minority with
good prognostic features. Radiotherapy fractionation for the following 3 months was again
audited.
Results In the 3 months preceding the audit recommendations 62 patients received
a total of 311 fractions of radiotherapy, giving an average of 5.0 fractions per patient. 54
patients (87.1%) received 20 Gy in 5 fractions, 4 patients received 2 fractions or less.
In the 3 months following audit 72 patients received a total of 265 fractions giving an average
of 3.7 fractions per patient. 42 patients (58.3%) received 12 Gy in 2 fractions and 23 (31.9%)
received 20 Gy in 5 fractions. These results indicate a 26% reduction in fractionation per
patient.
Discussion The number of fractions used to treat brain metastases has declined in this
centre in the 3 months after an audit meeting recommendation. This has resulted in some
saving of limited radiographer/machine resources. Re-audit will take place in future.42 Poster Presentations
THE LEEDS TECHNIQUE, DOSIMETRY AND TOXICITY OF
P01 3 FRACTIONATED TOTAL BODY IRRADIATION PRIOR TO
ALLOGENEIC BONE MARROW 'I'RANSPLAN'TATION.
i.E.Gerrard, R.E.Taylor, G.Pitchford, D.Gilson, J.M.Povall. and
A.Morgan., Cookridge Hospital, Leeds, LS16 6QB
Introdution Since 1989 we have used a relatively straightforward technique for giving total body
irradiation (TBI) , asing anterior and posterior parallel opposed ficids with the arms and fists acting as
compensators. The dosimetry, toxicity and outcome of48 patients treated with TBI using our technique
have been audited.
Methods All patients (26 adults, 22 children) treated by this technique were followed up The
technique will be described 14.4 Gy in 8 fractions over 4 days was prescribed to all patients with an
unrelated donor and 12 Gy in 6 fractions over 3 days to those with a sibling donor. From May 1994, all
children received 14.4 Gy regardless ofthe type ofdonor.
Results Lung dosimetry was - 6% to + 7% when the dose was specified to the lung maximum.
'I'he trunk doses were all within +/- 10% ofthe prescribed dose. Doses to other regions ofthebody
were less homogenous but clinically acceptable in that the doses were never less than minus 10% of
the prescribed dose. Thirty-eight patients developed mucositis requiring intravenous opiates.
Mucositis was significantly worse after 14.4 Gy than after 12 Gy and in adults than in children.
No cataracts have yet been seen. The radiation was not found to be a proven cause ofclinical
pneumonitis in our patients. There were no TBI related deaths.
In conclusion. our straightforward tecnique achieved reasonable dosimetry and was well tolerated.
P015
RETROSPECTIVE ANALYSIS OF DOSE
INTENSITY IN NEOADJUVANT
CHEMOTHERAPY OF BREAST CANCER
l.Shparyk*, Dept. Oncology, POB 2468, Lviv, 290029, Ukraine.
Dose intensity (Dl) in chemotherapy is defined as the
amount of drug delivered per unit time and is usually standardized
to body surface area as mg/m2/wk. A positive relation between Dl
and treatment outcome has been demonstrated not only in
advanced breast cancer (BC) but also in adjuvant setting. Only
few trials using Dl concepts have been performed in neoadjuvant
chemotherapy for BC. To determine if neoadjuvant chemotherapy
Dl influences treatment outcome in primar.y BC, 44 published trials
from 1985-1995 were retrospectively analyzed (4355 patient).
Regimens included such agents as Cyclophosphamide or Tiotepa,
Doxorubicin or Epidoxorubicin, Fluorouracil, Methotrexate, and
Vincristine or Vinblastine or Vinorelbine (from single drug therapy
to five-drugs combinations). Relative Dl (RDI) of each study
regimen was calculated against commonly used doses of each
drugs in single regimens (e.g 25 mg/m2/wk for Doxorubicin, 400
mg/m2/wk for Cyclophosphamide, 25 mg/m2/wk for Methotrexate,
1250 mg/m2/wk for Fluorouracil, 1.5 mg/m2/wk for Vincristine etc.).
Meta-analysis of chemotherapy trials for BC with some various
regimens have suggested that higher total RDI correlated strongly
with improved response rate (partial and complete response)
(r=0,48; p<0,001), and complete response (r=0,52; p=0,0028). It is
the first retrospective analysis on DI-response relationship (after
Hryniuk e.a. in adjuvant chemotherapy and metastatic BC) in
neoadjuvant chemotherapy of BC.
P014 DIAPHRAGMATIC PARALYSIS - A NEW COMPLICATION OF CONTINUOUS 5-
FLUOROURACIL? CA O'Doherty, BR McLaren, RT
Penson, ML Slevin, RTD Oliver and CJ Gallagher,, Department of Medical
Oncology, St Bartholomew's Hospital, London ECIA 7BE, UK.
100 consecutive patients whohad chemotherapydelivered by means of a
skin-tunnelled central venous catheter were reviewed retrospectively.
92% of patients had Groshong lines inserted and 8% of patients
Hickman lines. 65% of patients received chemotherapy regimens
containing continuously infused 5-fluorouracil. Rates of line infection
(11%), sepsis with no obvious focus (7%), line thrombosis (1%) and
axillary vein thrombosis (2%) were similar to those previously reported
elsewhere. However, 11% of patients receiving continuously infused 5
fluorouracil developed a previously undescribed complication of
diaphragmatic paralysis on the side ofthe line. All ofthese patients had a
Groshong line inserted on the right side. Clinical presentation consisted
ofeither right shoulder pain and/ordyspnoeaand diaphragmatic paralysis
was confirmed with X-ray screening of the diaphragms. This problem
was not seen in any patient receiving either intermittent 5-fluorouracil
infusions or regimens without 5-fluorouracil. We conclude that
diaphragmatic paralysis related to continuous 5-fluorouracil is a
previously undescribed complication and may be due to a local irritant
effectof5-fluorouracil delivered bythe side portof the Groshong line to
a site adjacent to where the phrenic nerve is closely related to the
subclavian vein on the right.
P016 VALUE OF CAl 5.3 IN MARKING RELAPSE IN
BREAST CANCER. T.K.Wheeler1, S.Stenning2,
S.Negus3, S.Picken1 and S.M. Metcalfe3. 1 Dept Clinical Oncology, and 3
Dept of Surgery, Addenbrookes Hospital,Cambridge, CB2 2QQ; 2 MRC
Cancer Trials Office, Camribdge CB2 2BW.
AIM. To determine any relationship between pattern of relapse
and raised levels of the tumour marker CA15.3 in patients
following primary therapy for breast cancer.
METHODS. Sequential patients treated for operable breast
cancer and with five or more years followup were analysed for
pattern of relapse. In 298 of these patients, levels of CAl 5.3
had been measured using the Centocor Assay kit (normal range
< 40 CA15.3 untis/ml plasma). Disease free survival curves
were calculated using the Kaplan-Meier method and were
compared using the log rank test. CAl 5.3 levels were compared
using non-parametric tests because the data were not
distributed normally.
RESULTS. Of the 298 patients, 66 had a clinically diagnosed
relapse. The sensitivity of CAl 5.3 for active disease was 25/66
(37.9%) and the specificity was 231/232 (99.6%). For distant
metastatic sites sensitivity and specificity was 53% and 97%
respectively. Overall, the hazard rate for relapse increased upto
years 4 and 5 after diagnosis for both node negative patients
(upto 5%) and node positive patients (upto 15%).
CONCLUSIONS. For breast cancer patients on follow-up, a
raised CA15.3 value gave a 96% probability of active disease
somewhere, and 73% probability of this active disease being at
a distant metastic site. Measurement of CA15.3 levels in
patients at risk (node positive and > 2 years after primary
diagnosis), or patients presenting with symptoms, may assist
diagnosis of relapse per se and diagnosis of relapse at distant
sites in particular.Poster Presentations 43
P017 CHANGES IN HORMONE RECEPTORS AND PROLIFERATION
MARKERS IN TAMOXIFEN TREATED BREAST CANCER
PATIENTS AND THE RELATIONSHIP WITH RESPONSE. A.
Makris', T.J. Powles', D,C. Allred , S. Ashley', M.G Ormerod4, M.
Dowsett3 'Royal Marsden Hospital, Sutton and Surrey, UK; 2University of
Texas Health Science Center, San Antonio, Texas, USA.
The primary aim of this pilot study was to establish whether there were
early changes in proliferation markers and hormone receptors which could
predict in individual patients, with primary breast cancer, their later
response or resistance to tamoxifen. Twenty-one women with primary,
operable, breast carcinomas were treated with tamoxifen 20 mg daily. Fine
needle aspiration (FNA) was used to obtain samples prior to the start and at
14 days and 60 days post-treatment. From these samples estrogen receptor
(ER), progesterone receptor (PgR) and Ki67 levels were determined using
immunocytochemistry and ploidy and S-phase fraction (SPF) using flow
cytometry. Tumour response was measured clinically according to UICC
criteria There were 12 responders (2 CR, 10 PR) and 9 non-responders (2
NC, 7 PD). Responders were more likely to be ER+ (p=0.002), PgR+
(p=0.006) and low SPF (p=0.06). At 14 days post-tamoxifen, the median
decrease in Ki67 (% cells staining) for responders was -4.8 and for non-
responders -0.15 (p=0 005). This decrease vas seen predominantly in ER+
tumours. The difference in SPF was not significant. A decrease in ER was
seen in 3/15 patients all ofwhom were responders A rise in PgR was seen
in 7/17 patients and all but one were responders. Similar changes for ER
and PgR were se-n at 60 days post-tamoxifen, however the reductions in
Ki67 and SPF at that time point were not related to response
Conclusion: We have observed a decrease in Ki67 and ER and a rise in PgR
after 14 days of treatment that was related to subsequent response These
observations provide validatory support for the use of this clinical-
biological model for testing the efficacy of new endocrine agents in the
clinical setting
PO19 IDENTIFICATION OF CLINICAL FACTORS
PREDICTING OUTCOME FOLLOWING PRIMARY
ChiEMOTHERAPY(PMT)FOR OPERABLE BREAST CANCER
PA Ellis 1, IE Smith 1, S Ashley 1, G Walsh 1, S Ebbs 2, M Baum 1, JA
McKinna 1 Breast Unit Royal Marsden Hospital, London, and Mayday
University Hospital, Croydon, UTK.
This study aimed to identify the clinical factors that predict for
subsequent outcome in patients with large operable breast cancer treated
with PMT at our institution between 1985 and December 1994. One
hundred and eighty five patients (pts) received the following regimens:
CMF or MMM (mitomycin, methotrexate, mitoxantrone) (76 pts); ECF
(epirubicin, cisplatin, infusional 5-FU) (75 pts); AC or FEC (34 pts),
followed by surgery, with radiotherapy (RT) given to those with breast
conservation. Median tumour diameter was 6cm and median followup 41
months.
Overall response rate was 82% with 36% obtaining complete
remission (CR). Twenty-three patients (12%) recurred locally as the first
site of relapse in the absence ofdistant metastases. Clinical responders had
improved disease-free survival (DFS)(p=0.009) and overall survival
(OS)(p=0.08) compared with non-responders. There was no association
between clinical or pathological CR and survival. Pre-treatment clinical
axillary node positivity was a significant predictor of worsened DFS
(p=O.OOOl), OS (p=0.0001), and local recurrence-free survival
(LRFS)(p=0.03) but post-treatment pathological axillary node status did
not predict for survival. Twenty-nine patients in clinical CR following
PMT who electively did not have surgery and were treated with
radiotherapy (RT) alone had a significantly increased rate of local
recurrence compared with partial responders having surgery + RT
(p=0.02). There were no differences in DFS or OS between these groups.
On multivariate analysis clinical axillary node status was the only
independent predictor ofOS and DFS, and LRFS.
Pre-treatment clinical axillary node status is a major predictor of
outcome following PCT, whereas post-treatment pathological axillary
node status is not. Complete clinical response does not define a more
favourable subgroup compared with those not obtaining CR. Biological
predictors ofclinical outcome following PMT are required.
P01 8 POLYCHEMOTHERAPYWITH INFUSIONAL5-FU (iFU) IN LOCALLY ADVANCED BREAST CANCER
-5 YEARS' EXPERIENCE AT A SINGLE CANCER CENTER. 1DA
Cameron, 2A Bowman, 1H Gabra, 2M Stewart, 'RCF Lponard. ' Breast Unit
&2ICRF Medical Oncology Unit, Western General Hospital, EDINBURGH.
The use of iFU in metastatic breast cancer is associated with an improved
response rate and altered toxicity profile. We hypothesised that the
combination of iFU with other effectivedrugs could improve the primary
medical management of inoperable breast cancer.
Between 1991 & 1998 we have treated 73 women for a maximum of 12
weeks with iFU in combination with otherdrugs ; continuous 5-FUa 200
mg/m2/daywith weekly adriamycin (20- 30 mg/iM2) (AcF), with threeweekly
cisplatin 60 mg/M2 and epirubicin 50 mg/M2 (ECF), orwith three weekly
cydophosphamide 750 mq/m2 and methotrexate 50 mg/m2 (CMFinf); or24
hours 15-FU @600 mg/m with weekly adriamycin (20 - 30 mg/mr2) and
cyclophosphamide 150 mg p.o. for 3 days:
CAF
AcF
ECF
CMFinf
no.
17
33
14
9
median age
51
50
46
81
response
76%
76%
79%
67%
median survival
4.7 years
> 4 years
> 2 years
>2.5 years
2 yearsurvival
80%
70%
90%
100%
No significant cardio-toxicity was seen with any regimen, and the overall
response rates were: pCR4 (5%) CR 11 (15%) PR e (80%) SD 12 (16%)
and PD 3 (4%). 46 (63 %) were operable atthe end of the three months'
therapy, and the median survivalswere no different forthose remaining
inoperable or the 34 (47%) ofpatientswith inflammatory disease at
presentation. Women with ER positive tumours received tamoxifen for upto
5 years aftersurgery, and had a significantly bettersurvival (p < 0.0002).
This retrospective analysis suggests that the use of iFU might improve the
medium term survival for patients with locally advanced breast cancer.
P020 ALLELIC IMBALANCE AT CHROMOSOME
17P13.3(YNZ22) AND POOR PROGNOSIS IN
BREAST CANCER. A Thompson,M Clay,D Crichton,R Elton,U
Chetty, C Steel. Dept ofSurgery, Ninewells, Dundee, DDl 9SY.
Molecular and immunohistochemical studies of genetic events on
chromosome 17p were prospectively compared with conventional
clinical and pathological parameters and disease behaviour at a
minimum 72 months follow up.
In a series of91 patients with primary operable breast cancers, 37/91
(41%) patients had disease relapse and 23/91 (25%) had died during
the follow up period. Allelic imbalance at the YNZ22 locus
(17pl3.3) examined by Southern blotting, demonstrated in 33/63
(52%) informative patients, was significantly associated with disease
recurrence (p<0.01, 2df, Cox analysis) and showed a trend towards
impaired survival (p=0.08, 2df, Cox analysis) after a mean follow-up
of 84 months for survivors. By contrast, p53 mutation (in 10/60,
17% of cancers), p53 allelic imbalance (in 23/56, 41% informative
patients), p53 mRNA expression (in 47/87, 54% patients),' p53
mRNA overexpression (in 24/87, 28%) or p53 protein expression
(detected in 25/76, 32%) were not associated with disease behaviour.
There was no significant association between allelic imbalance at
YNZ22 and any abnormality ofp53 DNA, RNA or protein.
Allele imbalance at 17pl3.3 (YNZ22) serves as a marker of poor
prognosis in breast cancer. As yet unidentified genes on 17pl3.3,
distinct from p53, are therefore likely to be of clinical importance in
breast cancer.44 Poster Presentations
P021 HIGH DOSECHEMOTHERAPYWITHAUTOLOGOUS
PERIPHERALBLOOD STEMCELL(PBSC) RESCUE
FOR METASTATIC BREAST CANCER: AFIVE YEAR EXPERIENCE.
H.Gabra*1.3, J. Craig2, DA Cameron3, RCF Leonard3 1ICRF Medical
Oncology Unit, 2Blood Transfusion Service, Royal Infirmary,
3Directorate of Clinical Oncology Western General Hospital, Edinburgh.
We report our experience of high dose chemotherapy with PBSC rescue
between July 1992 and February 1997, representing an update of a
recently published series, including more patients and longer follow-up
(Cameron et al, BJC 76, 2013-2017, 1996). Forty-six patients with
metastatic breast cancer underwent 1 of 3 induction protocols. Patients
with stable or responsive disease underwent high dose chemotherapy
with either etoposide (1600 mg/M2 ) and melphalan (140 mg/M2)
(n.10), or Thiotepa (500 mg/M2) and melphalan (140 mg/M2)
(n=36). Patients were rescued with G-CSF mobilised PBSC.
Of 46 women after high dose chemotherapy, 11/46 achieved PR and
21/46 achieved CR. The only significant (WHO grade 3/4) non-
haematological toxicity was mucositis. Median time to neutrophil
recovery ( > 0.5 X 109/l) was 14 days, and to platelet ( > 20 X 109/1)
recovery was 10 days. There were no treatment related deaths.
This approach demonstrates the feasibility and safety of this procedure
and paves the way for large randomised studies
P023 SYNERGISTIC ONCOGENES IN TRANSGENIC MICE: A REPRODIJCIBLE MAMMARY CARCINOMA MODEL,
E. Tadros, K. Williamson, C. Pope, D. Kirk and W. Odling-Smee, Dept of
Surgery, QUB, Institute of Clinical Science, Belfast BT12 6BJ.
Several oncogenes have been associated with human
and murine mammary carcinoma. Sinn(1987) reported the
development of mammary tumours in transgenic c-myc and v-ha-
ras oncomice and their synergistic activity. We aimed at
reproducing such a model to study the angiogenic activity of
mammary tumours and angiosuppressor agents. We have
successfully inbred v-ha-ras and c-myc Transgenic oncomice
and crossbred them to yield dual carriers. Virgin female dual
carriers developed single and multiple mammary tumours. These
were observed daily from weaning age and their age at first and
subsequent tumour detection was recorded. The tumour
diameter was measured every 2 days and the mouse was
weighed. Mice were sacrificed after 4 weeks of observation and
the tumours harvested for histological identification. Mammary
tumours were detected in 51 out of 109 observed mice (46.8%).
This is less than 100% reported by Sinn(1987). The age at which
half the mice developed tumours (T50) was 62 days ( range 43-
104). Mean diameter offirst tumour detected was 5.4 mm (range
3.2-8.5).Mean weight at onset of the first tumour was 23.9 grams
( 21.8-25.8). More than half developed single tumours.
Histologically these tumours were adenocarcinomas with a
papillary component.
No of 1 2 3 4 5 6 Tota
tumours/mouse I
No of mice 33 5 4 1 3 5 51
% ofgroup/total 64.7 9.8 7.8 2.0 5.9 9.8 100
Table 1 shows the incidence of multiple tumours.
P022 PLANN E UVANTCHEMOT HERAPY INPRIMARY CARCINOMAOFTHEBREAST -THEUSEOFBIOLOGICAL
PARAMETIERSTOPREDICTrHISTOLOGICALGRADE,RKGegoiy,
TJPowles, MOrmerod, JTiley,MDowset Royal MadenHospial Lonon.
Oneofthemanconcemsrelatingtotheicreaseduseofneoadjuvant
chemotherapyinpimarycminoraofthebreast S h at anumber ofpatientswith
lowgrade,nodenegativeuourswillbeovertreatedinthattheywouldbe
unlikelytoreceivechemodterapyintheadjuvant tting.Histologicalgrdeisan
establishedprgnosticmarkerandisoneoftheparametersuponwhich
oncologistsbasedecisionsregadingadjuvantthray.
Aim:Toinvestigateamethodforpredicinghistologicalgrdeonadigosticfine
needleaspirate(FNA)inpatientswithpsimasycarcinomaofthebreast
Methods:FNAswereob fimpatientswithp marycarcinomaofthe
breast Thesampleobtainedwasthensuspended inEaglesessentialmedium.
Cytospinslideswereproduced,oneslidewassenttothecytologistfordiagnostic
purposestheremanderwerestoredat-70candtheremainigsamplewassnap
fiozen. ProliferationasmeasuredbyMIB-1 statuswasassessed
immunocytochemicallyandDNAploidyands-phasefraction(SPF)wer
assessedbyflowcytometty.
Results: Intotal53patientshadapositiveFNA,ofthese 17%weresubsequently
foundtohavegradeI,490/ograde and34%grademtumours. Ofthosepatients
withgradeItmouursallhaddiploidtumourswithalowSPFandMlB-l
expression(asdefinedbythemedianscoresforthepatientgroup).Incontrast89%
ofpatientswithgrdeHItumourshadaneuploidturnourswithhighMIB-l and
SPF.
Summary: Wehavedemonsiatedthat DNAploidy, SPFandMI3-1 statuscan
allbedetemilnedonasinglediagnsticFNAandwhentheseparametersare
combinedtheyprovideanindicatoroftuourgrade.Thismayproveusefulin
selectingpatientswhomaybenefitfiomneoadjuvantchemotrapy.Followupof
patientswill allowustodetenninewhederthesepathologicalindiceshavethe
progosticpoweroftunourgrde.
P024 NAVELBINE (NVB) &FRACTIONATED DOSE DOXORUBICIN P02 (DX) IMPROVES IST LINE ADVANCED BREAST CANCER
(ABC). AN OVERVIEW OF 3 PHASE II TRIALS.
J. Carmichael1, R. Hefg2, D. First3, M. Pawlicki4, F. Le Bras5,
F. M. Delgado5, P. Danel5 and S.A.N. Johnson Nottingham City Hosp UK; 2ELAN Brazit;
3Ankara, Turkey; 4 Krakow-Poland; 51.R.P.F., France; 6Taunton & Somerset Hosp, UK
Aim.-Anthracycline combinations represent the most powerful chemotherapeutic
approach in the treatnent ofABC, but their limiting toxicities are neutropenia and
cardiac impairment. NVB as a single agent has demonstrated a high activity and
good tolerance in ABC: 40%-60% response rate (RR). Promising results have
previously been obtained with NVB 25 mg/M2 Dl & 8 + DX 50 mg/M2 DI (q 3 w):
74% RR (21% CRs), mainly in visceral sites (JCO 94). This was confirmed by a
significant survival advantage observed in pts with liver metastases treated with
NVB + DX compared to CAF (ESMO 96). Dividing the DX dose and administering
it at weekly intervals may reduce the cardiotoxicity without substantially impairing
the efficacy. 3 studies were conducted withNVB + DX, both at 25 mg/m2 DI & 8 (q
3 w, 8 cycles) to check the efficacy, improve the tolerance and to ease outpatient
administration. Results.- 120 pts were included: age 30-73y; PS 0-1: 85%; visceral
involvement: 52%; adjuvant C: 18%. 668 cycles were administered; WHO grade
(G) 3-4 neutropenia: 24%; infection G 3: 6/120 pts; G 3-4 nausea/vomiting: 17 pts;
G 3-4 constipation 1.5%; G 1 peripheral neuropathy: 13%; G 3 alopecia: 53.5%. No
G 3-4 cardiotoxicity. The RR ranges from 70% to 77% (18-35% CRs) RR on
visceral sites: 56%-86%. Conclusion.- These results confirmed that NVB + DX (25
mg/M2 D 1 & 8) has major and reliable activity as 1st line therapy. Given its very
favourable tolerance, low morbidity and absence of life threatening cardiotoxicity,
out patient administration of this regimen could be recommended as 1st line
treatrnent for ABC.Poster Presentations 45
P025 USAGE OF AN INTERNET-BASED CANCER
INFORMATION SERVICE FOR THE GENERAL
PUBLIC (CANCERHELP UK) VIA THE INTERNET AND IN
CLINICAL SETTINGS. S J Tweddle', C James,' D Davies,2 P
Harvey,3 L Woolf4, N James.' 'CRC Institute for Cancer Studies, The
University ofBirmingham, Edgbaston, Birmingham B15 2TA, 2School
ofMedicine & Dentristry, The University ofBirmingham,
Birmingham, B15 2TJ, 3Birmingham Oncology Centre, Queen
Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, 4BACUP, 3
Bath Place, London, EC2A 3JR.
An Internet-based cancer information service for the general public,
CancerHelp UK, is being evaluated through usage in clinical settings
and on the Internet.
In the study ofusage in clinical settings data are gathered through
pre- and post- use questionnaires, interviews and observation of
patients and carers in 2 hospital clinics and 3 GP surgeries; participants
are asked about information needs and information media preferences.
Post-use questionnaires ask about the ease ofuse, design and
usefulness ofthe service.
The study ofInternet usage compares data from two samples ofusers
over two four month periods. Feedback forms completed by Internet
users and user activity recorded on the computer server generate data
about users, their evaluation ofthe service and usage patterns.
80% ofthe participants in clinical settings had only occasionally or
never used a computer; 92.3% had rarely or never used the World
Wide Web; 22.1% declined to use CancerHelp UK altogether. 82% of
the first Internet sample (89) respondents were female and friends and
relatives were the largest group ofrespondents (36%). Initial findings
show that users are positive, find the service easy to use and are happy
with existing information but wish for additional detailed information
on treatment and specific cancers.
P027 PATIENT HELD RECORD
M Buckley. I G Finlay.
Velindre NHS Trust, Cardiff, Wales, UK
Object. Following a survey held with general practitioners (GP's)
and patients (1994) the author identified-the need to develop a patient
held record (PHR) for cancer patients.The aim ofsuch a record was to
help inmprove communication between the hospital,GP's and primary
health care team. The objective of the pilot was to identify if such a
record would be useful in improving communication between the
hospital and the community services.
Method. A working group, which included GPs compiled a draft
patient held record. The record was piloted for 4 months on 100 out-
patients. The 100 patients were individually interviewed with a
relative or a carer and were given verbal and written guidelines in the
aim and use ofthe record.
Results. After 4 months of the pilot the first level analysis was
performed. The data collection tools were questionnaires designed for
the 100 patients and 100 health care professions. Overall response
rate = 83.5%. The results suggest that the PHR would be a useful aid
in improving communication between services when used correctly.
Patients found the record acceptable and valued the way in which
they were consulted about what was being recorded.Patients and
doctors had different attitudes and expectations of the patient held
records. GP's looked at it as a management and communication tool,
whilst patients mostly perceived the patient held record as a personal
document for reference, safety and to be able to "keep in control".
Hospital stafffailed to enter details in the record, did not readily hand
out PHRs to new patients and did not encourage patients to
participate in their core planning documentation.
Conclusion. The pilot shows that PHRs are welcomed by patients,
GP's and other agencies. However resistance to change was evident
amongst hospital staff. The obstacle from relates to approach,
attitudes, perceptions and anxieties ofthese health care professionals,
further education andtraining is required.
P026: COULDTHE ROTTERDAM SYMPTOM CHECKLIST (RSCL) BE P026 USED IN THE ROUTINE CARE OFPATIENTS WITH CANCER?
A PURCHASER-PROVIDER COLLABORATION.
P Revell', JP Walsworth-Bell2, MS Young-Min', SWardle2, JM Anslow'.
'Dept Haematology, Staffordshire General Hospital, Stafford ST16 3SA,
2Dept Public Health Medicine, South StaffordshireHealth Authority Stafford, ST16 3SR.
In discussions around cancer treatment services in 1994 it became apparent that much
cytotoxic chemotherapy is for palliation, not cure. Quality oflife issues therefore become
important in purchasing decisions and the patient's own perception is perhaps the most
relevant.
A 2 year pilot study was initiated to see if substantial numbers of cancer patients could
provide on-going quality of life data using a validated instrument and with minimal
disruption to themselves and the clinic - using current structures rather than new
resources. Patients in the haematology clinic with CLL and LG-NHL were chosen as
chemotherapy is palliativetbut with a low number ofexpected deaths in the study period
(observed = 5/68).
A reformatted RSCL (2 sides of a single A4 sheet) was sent by post, with a personal
covering letter, in advance of the next scheduled clinic visit. The patient was asked to
assist us by filling in the form at home on the day before the clinic and hand it in when
attending. A maximum of4 episodes were requested at a minimal interval of 3 months.
184/207 (89%) of forms were returned first time; 51/68 (75%) of patients returned forms
for all their episodes first time. All non-responders "caught up" with repeat forms sent
for subsequent visits.
Anonymised forms were sent to the HA for analysis. The instrument appears valid in this
context though the 'Work" and sexual activity modules seemed less relevant to this
(generally older) group ofpatients - removal of these 2 aspects did not meaningfully alter
median scores.
It became apparent during the pilot that although participation prompted patients into
discussing subjects in the clinic they might otherwise not have mentioned, it was of
limited real-time usefulness. A further study is planned to see whether the checklists can
be expeditiously scored and the information used in the clinic. Could 'Youtine"follow up
of cancer patients ultimately be replaced by targeted clinic attendances based on postal
quality oflife data?
P028 PULSED FIELD GEL ELECTROPHORESIS IN NORMAL TISSUE RADIOSENSITIVITY
TESTING. AE Kiltie, A Ryan, CJ Orton, CML
West, JH Hendry. Department of Experimental Radiation Oncology,
Paterson Institute for Cancer Research, Christie Hospital NHS Trust,
Manchester M20 4BX.
Using clonogenic assays, fibroblast survival has been found to
correlate with radiotherapy late normal tissue reactions, but such
assays take too long to be of use in predictive testing of individual
patients. It has been shown that residual DNA damage in fibroblasts
as measured by pulsed field gel electrophoresis correlates with
clonogenic survival, when radiosensitive ataxia-telangiectasia lines are
included. We have undertaken a study which confirms this correlation
using fibroblasts cultured from nine pre-therapy cervix cancer patients
(SF2values ranging from 0.147 to 0.322). Tritium-labelled cells were
irradiated in plateau phase and allowed to repair for 24 hours, before
cell-agarose plugs were made and lysed prior to PFGE. The residual
damage slope (from 60-15OGy) correlated with Dbar both when two
radiosensitive cell lines were included (r=-0.91, p<0.001) and for the
vaginal fibroblasts alone (r=-0.83, p=0.006). The fraction of activity
released (FAR) at 15OGy correlated with residual damage slope (r--
0.92, p<O.001), suggesting that a single dose point may be used in
studying patient material.
Primary biopsy material would allow a more rapid assay using PFGE,
but cells cannot be pre-labelled. We have developed a simple method
ofgel imaging, using relatively inexpensive CCD TV equipment and
commercially available computer software to analyse SYBR green
stained gels, which is as sensitive as radioactive prelabelling.46 Poster Presentations
P029 FUNCTIONAL ASSAY OF Pgp ACTIVITY
IN SOLID TUMOR SPECIMENS EX VIVO,
T. Bogush, G. Smirnova, E. Chmutin, Cancer Research Center,
Moscow, Russia
It is generally accepted that the results of direct immunohisto-
chemical determination of Pgp expression poorly correlate with
the chemotherapy outcome and that a functional assay is neces-
sary for assessment of Pgp function. The commonly used func-
tional assays of Pgp activity are applied to cell suspensions only,
and no functional intravital assay is available for investigation of
solid tumors. We have developed a functional assay of Pgp activ-
ity in solid tumor specimens based on assessment of Pgp response
to Pgp modifiers. The measured parameter is the intracellular ac-
cumulation of doxorubicin (DOX) which is Pgp-dependent. To
measure DOX intracellular accumulation in solid tumor speci-
mens, we have adapted the previously developed fluorimetric ap-
proach which was designed for measurement of doxorubicin
(DOX) intracellular transport and binding to DNA in cell sus-
pensions. The method is based on the phenomenon of DOX fluo-
rescence quenching after interaction of the drug with DNA but
not with other cellular macromolecules. When a solid tumor
specimen is incubated with DOX, the fluorescence of the drug in
the incubation medium decreases reflecting both intratumor pene-
tration and intracellular accumulation. After reaching the stable
rate of fluorescence quenching a Pgp modifier is added to the in-
cubation medium and DOX fluorescence quenching is further
monitored. If the modifier acts on Pgp, the increase of the speed
of DOX fluorescence quenching in incubation medium occurs.
Using this methodology we have shown the Pgp functional activ-
ity in solid murine resistant Ehrlich tumor and the absence of
such activity in the sensitive one. We now apply the developed
methodology for investigation of human biopsy solid tumors to
reveal the relationship between the tumor Pgp functional activity
and response to chemotherapy. Supported by the Russian Foun-
dation for Basic Researches.
P031
LASER INDUCED HYPERAEMIA- HOW MUCH, WHEN AND
WHY?
A R Gillams, A Waldman, S G Bown,* G Buonaccorsi* and WR Lees
The Departments of Medical Imaging and The National Laser Centre,*
The Middlesex Hospital, London, UK.
Object: To study the effect of interstitial laser therapy on
perfusion in patients with liver tumours.
Methods: Twelve patients who had been referred for interstitial
laser therapy were studied with dynamic helical contrast CT both before
and after treatment. 5/12 were restudied at 2-3 months follow-up.
Following a bolus of intravenous contrast a single axial CT slice was
performed through the lesion at 1.1 second intervals. Scanning
commenced at 12 seconds after the onset of the injection and continued
for 33 seconds. Region of interest measurements were made over the
aorta, portal vein, adjacent liver and distant normal liver.
Results: Following laser therapy an area ofhyperaemia, seen as a
focal increase in contrast enhancement, develops around the lesion.
Two patterns were identified: circumferential or involvement of the
whole tumour bearing segment. Up to a four fold increase in hepatic
arterial flow was observed at 12 hours post treatment. There were
milder increases in portal venous flow. This effect persisted but was
less marked at 3 months follow up.
Conclusion: Laser therapy induces a marked increase in hepatic
arterial perfusion around tumours. It is possible that this effect could be
used to improve delivery of chemotherapeutic agents specifically to the
tumour.
P030 A QJANTITATIVE CELLJLAR (tRDINE) MODEL OF CYYTOXIC
ORAL MJCOSITIS. AM WABDLEY, JH SCAPFFE, CS PIE.
CRC DepartTelt of Epithelial Biology, Christie Hospital & Paterson
Institute, Manchester M20 4BX, UK
Oral mucositis (OMhI) is a rmajor and often dose-limiting side-effect of
cytotoxic agents, Manipulation, with cytokines, of stem cell kinetics to
render them more resistant to darmage before treatment and subsequently
stimulate them to proliferative more rapidly after therapy may abrogate
this toxicity. The investigaticn of such agents requires a quantitative
cellular model.
BLF -mice were given CM-inducing therapy (head-irradiation and/or
chemotherapy with 5-fluoroaracil, melphalan or blecmycin). Animals were
sacrificed daily after being pulsed with brrrdeoxyurid:ne. Using a
Zeiss Axichome TM cacputer assisted microscope cells/mm epitheliun and
cells/m basement menbrane were counted for ventral tcngue and buccal
mucosa. The basal labelling-index was calculated. There is a
progressive decrease in cellularity to reach a dose dependent nadir
follcwed by rapid repopulaticn to baseline levels. Cramplete suppression
of DNA synthesis, is follcwed by a progressive regenerative increase
with a nmximm coincident with cellular nadir. This in vivo model
describes the changes in epithelial cellularity which cause CM and will
be used to investigate the potential of various agants to protect against
or accelerate recovery from therapy induced mnuoitis.
P032'
DIFFERING PATTERN OF IN VITRO CEA EXPRESSION AND SUPERNATANT RELEASE
BY AUGMENTED COLORECTAL CANCERCELLS
M.H.S. COLLIE; J. BHATIA; R.AUSTEN; M. CWINSLET, DeptofSurgery, Royal Free
Hospital, Pond St, London NW12.
Colorectal cancercells are known to beheterogenous expressors ofthetumourassociated
antigen Carcinoembryonic Antgen (CEA), which may betargetted byantibodies. The
efficiency ofthis antibody guideddetection and treatment iscompromised by the heterogeneity
ofexpression ofthe CEA.
Certain chemical agents, cytotoxicdrugs and environmental changes have been shown to
increase CEAexpression in colorectal cancercells.
In this study, three colorectal cancercell lines, Lovo,HT29 and Colo, known to be high, lowand
non-expressors ofCEA were grown in monolayercellcultureforfive days in the presenceofa
differentiating agent (ButyricAcid, Theophylline, 5-AzactidineorInterferon), orwvith altered
environment(Acid medium, alkaline medium, starvationorhypoxia)orwith 5Fluorouracil. The
cells were then immunostained and theirCEAexpression measured by Fluorescein Activated
Cell Sorting. Radioimmunoassayofthe supematants from thecultureflaskswas performed to
measure CEA released.
Significantchanges in CEAexpression and release as analysed bytheWilcoxon Rank Sum
test(P<0.05) were asfollows:
Starve Acid Alkali H|o ButAc Theo 5-Azac IFN 5FU
Colo Expi Expt
HT29 Exp Exp Expt Expi Exp Expi Expi
Relt fRetl
Lovo Exp Exp Exp Exp Expi
Rel Rel Rell Rol Rel Roll
Thechanges in CEAexpression were notmirrored bysimilarorreciprocalchanges in
supematantrelease, although results wereinfluenced by naturalexpression levels.
In vitro, itisconcluded thatchemicalagents orenvironmentalchangeswhich lead to
augmented CEAexpressionbycobrectal cancercellsdo notcausematching increases in
CEAsupematant release. Ifthe same mechanism applies invivo, augmentation may not
necessarily increase serum CEA levels, with resultant highnon-specificantibody binding and
background noise.Poster Presentations 47
P032B
GROSS VARIATION IN CEA EXPRESSION AUGMENTATION BY DIFFERENTIATING AGENTS
M.H.S.COLLIE, N.J.BRAOLEY, M.C.WINSLET, DeptofSurgery, Royal Free Hospital, PondSt.,
London NW12.
Colorectal cancer cells areheterogenous expressors of thetumourassociatedantigen
Carcinoembryonic Antigen (CEA). Itispossibe totarget5EA on tumour cells in vivo with
anti-CEA antibodies, conjugated to radioisetopes orcytot6xic drugsforthepurposes of
detection and treatment. The efficiencyofthis antibodyguided detection iscompromised by
the heterogeneity ofexpression ofthe CEA.
This study compared the effects of4differentiating agents, (Butyric Acid,y-Interforon,
Theophylline and 5-Azacytidine) on 3 colorctl cancercell lines, Lovo, HT29 and Colo,
known to be high, low and non-expressors of CEA respectively. The cells weregrown in
standard tissue culture with oneoftheagetsfor 5 days. beforebeing harvestd and
immunostained for CEA. Thedegree of CEA expression vwsanalysed by Fluorescein
Activated Cell Sorting.
Average Fluorescence of Cells:
Control
544.0 ±
156.3
18.3 ± 2.6
9.86±7.2
But Acid Interferon Theoph
768.2 ± 807.4 ±45.2 575.07
185.6 ±117.8
45.2 ± 5.4 33.1 ± 3.2 30.9 ± 2.4
11.5 ±2.2 13.2 ±4.7 61.9 ±35.9
5-Aucyt
238.6±28.3
29.4 ±6.031
_78.6± 35.3
Different colorectal cancer cell lines may be induced by various differentiating apnts to
increase their expression of CEA, but they do not appear to share common pathways to CEA
expression.
Using a combination of agents may be a more efficacious way of inducing the increased CEA
expression of a typical heterogenous colorectal cancer.
p034 A PHASE II STUDY OF INTRAVENOUS GAMMALINOLENIC ACID
(GLA) PRE-TREATMENT IN PATIENTS WITH PANCREATIC OR
COLORECTAL CANCER TREATED WITH 5-FLUOROURACIL (5-FU).
R Btyoe2, JA Ledewmi, I Taylor', C Bmnas', RCGRuselI,AHatfield', 'UnivnityCoiegeLondon HospitaI
Lon UK,2SotiaPhrmnaceltcalsld, Stirling UK
GLA is cytotoxic to pancreatic cancer cell lines and synergism has
been shown when it is added to conventional cytotoxics in vitro.
Twenty patients with histologically confirmed advanced unresectable
pancreatic (18) or colorectal (2) carcinoma have been treated with
intravenous GLA 0.84g/kg (0.28g/kg for the last 5 patients to reduce
haemolysis and administration time) followed by 12 weeks'
continuous infusion with 5-FU 300mg/m2 week. Patients had
Karnofsky Performance Status >60% and gave written informed
consent. Two are still receiving 5-FU. Four completed 5-FU as
scheduled, 4 completed but required dose reduction or interruption
due to toxicity, 5 withdrew because of5-FU toxicity or Hickman line
problems and 5 died before completing 12 weeks. Grade 4 toxicities
were mucositis (1), planiar-palmar erythema (1), vomiting (1). Four
patients still survive, the longest lived for 389 days to date. Kaplan
Meier analysis of survival times yields a median of201 days for all
patients, and 200 days when restricted to patients with pancreatic
cancer. The data from this study suggests GLA does not result in
any significant increase in clinical toxicity of 5-FU and may be a
useful adjunct to conventional chemotherapy in advanced pancreatic
cancer.
P033 PROTOPORPHYRIN IX FLUORESCENCE IN THE
DIAGNOSIS OF DYSPLASIAIN BARRETT'S OESOPHAGUS
M A Jahan, I S Tait, E L Newman, A Cuschieri,
Department of Surgery, Ninewells Hospital, Dundee,
Background and aims-The vast majority of oesophageal adenocarcinoma
cancers arise on a background ofBarrett's metaplasia.The increased risk
ofmalignant transformation in Barrett's is between 40 -150 %. Patients
with Barrett's oesophagus are followed up by endoscopic surveillance to
detect dysplastic and malignant change. The current practice oftaking
multiple random biopsies has a poor sensitivity and specificity in
detecting high grade dysplasia and early adenocarcinoma. We have
studied delta-aminolaevulinic acid (ALA) induced protoporphyrin IX
(PpIX) fluorescence as a marker to target endoscopic biopsies. Methods-
20mg/kg ofALA dissolved in orangejuice were administered orally 4-6
h before endoscopy to 40 patients with Barrett's oesophagus and 4 with
oesophageal cancer. PpIX fluorescence was excited by a non-laser blue
light source. Biopsies were taken from both fluorescent and non-
fluorescent areas and submitted for histology. Results-70 biopsies were
analysed histologically and compared against fluorescent and white light
endoscopy.The sensitivity and specificity of diagnosing dysplasia in
Barrett's and cancer using fluorescence were 35.7% and 77%
respectively compared to 28.5% and 85.5% for conventional white light
endoscopy. These differences did not reach statistical significance. Side
effects were minimal, one patient withdrew from the study, two others
developed mild cutaneous sensitivity. Four developed mildly elevated
liver enzymes which resolved within 48 hours. Discussion-Sensitivity
was improved by the use offluorescence to guide biopsies, though the
effect was small. Current efforts are focused on better matching ofthe
light source with the absorption peak ofPpIX efficient delivery oflight
via an ultraviolet fibre. We expect improved fluorescence excitation and
enhanced sensitivity with the new apparatus.
P035 TUMOUR LOCALISATION OF AN ANTI-CEA SINGLE
CHAIN FV ANTIBODY IN COLORECTAL CANCER
A. Mayer', G.Boxer', D. O'Malley', K. Chester', B. Davidson2, M.C. Winslet2, A.J.W. Hilson3,
R.H.J. Begent'. (CRC Targeting and Imaging Group on behalf of the phase 1I'1 committee,
Dep. ofClin. Onc., 2Dep. ofSurgery, 3Dep. ofMed. Physics, Royal Free Hospital MS, London)
Patients undergoing resection of primary or recurrent colorectal cancer
are enrolled into a phase I study in order to investigate the potential of
Radioimmunoguided Surgery (RIGS®D) to localise tumour deposits using an
anti-CEA single chain Fv (scFv) antibody. ScFvs consist ofthe variable heavy
and variable light chain region tethered by a flexible linker and are as such the
smallest antibody fragments to retain full binding capacity.
Patients receive 25I labelled MFE-23-his, an scFv antibody derived from
bacteriophage technology with high affinity for CEA (Chester et al, 1994) 24,
48 or 72 hours prior to operation. The abdomen is scanned after traditional
exploration with a hand-held gamma-detecting probe (Neoprobe®1000
instrument). The endpoint ofthe study is the correlation ofresults ofthe probe
with histology and counts of the resected specimen obtained by a laboratory
gamma counter.
Preliminary results show selective tumour localisation in 2 patients
undergoing resection of liver metastases 72 hours after injection of the
antibody. RIGS findings correlated with histology in 5 patients with primary
tumours resected 24 (4 patients) or 48 hours (1 patient) after injection. Due to
the clearance of the antibody higher tumour to blood and tumour to normal
tissue ratios were found 72 hours after injection, namely 13:1 and-4.8:1,
allowing improved discrimination oftumour and normal tissue.
These results show that scFv can be successfully prepared and used for
RIGS procedures. Further improvements of the technique should allow
detection of small volume disease and therefore improve selection of patients
for adjuvant treatment, particulary antibody-targeted therapy.
=
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P036 THE EFFECTS OF UROGRAFIN ON THE PARTICLE SIZE AND THE UPTAKE OF LIPIODOL IN TARGETED THERAPY
FOR HEPATOCELLULAR CARCINOMA R.A.M. Al- Mufti,
L Tuwau, KE.F. Hobbs, M.C. Winslet. University Department
ofsurgery, Royal Free Hospital School ofMedicine, Pond Street, London, NW3 2QG.
Lipiodol, an iodinated e.thyl ester derivative of poppy seed oil, has been
used in targeted therapy for primary and some metastatic hepatic cancers. Lipiodol
is insoluble in water, and Urografin (diatrizoate) is used clinicaily to emulsify
Lipiodol prior to its intra-arterial injection. The effect ofUrografin in combination
with Lipiodol was assessed in tissue cultures ofHep-G2 (hepatoma) cell line. The
cell cultures were exposed to 2% Lipiodol alone and 2% of Lipiodol with 2%
Urografin for variable duration (3, 6, 12, 24, 48 and 72 hours). The uptake and
retention ofLipiodol was assessed using computer-assisted image analysis. The size
of the Lipiodol partictes were measured after 2 minutes agitation of the oil
suspensions with cultum media.
r rtl mr fild InI (+/- SD)
< 10 p 10-25p 25-50 5l 100p >l00 Total
2% Ulpiodol 890(101) 110(38) 17(3) 4(1) 4(1) 1,025
2%Upiodol +Urografin 575 (73) 220(56) 21(4) 7 (2) 8 (2) 831
The mean size of the Lipiodol particles when combined with Urografin
was considerably larger than that ofLipiodol alone, with a reciprocal reduction in
the numberofPanicles.
Quantification ofLUplodol uptake bycomputer assisted Image analysis
(Optical Density / computerised arbitrary units)
3 hounr 6 hours 12 houn 24 houn 48osrs h 72 ours
2% Upiodol 52.2 91.4 92.4 131.2 139 142
2% Up. + Urografln 49.4 59.8 68.8 89.8 115.4 128
The addition ofUrografin to Lipiodol resulted in a significant delay in the
uptake ofLipiodol by the cancer cells in vitro. A similar phenomenon in vivo may
interfere with the delivery of Lipiodol-targeted therapy for these tumours. The
continued use ofUrografin to dissolve Lipiodol in clinical pracice requlres firher
cvaluation.
P038 SURGERY PLUS CHEMOTHERAPY VS
CHEMOTHERAPY ALONE FOR PRIMARY
INTERMEDIATE- AND HIGH-GRADE GASTRIC NHL R.A.
Popescul, A.Wotherspoon2 and D.Cunninghaml TheRoyalMairden
NHS Trust, Sutton, Surrey, Departments oflMedicineand
2Histopatbology
Primary gastric lymphomas (PGL) have traditionally been treated
with surgery followed by chemotherapy or radiotherapy. Surgery
was thought to improve staging, optimise local disease control and
reduce risk of perforation or bleeding, but its role has recently been
questioned given improved CT and endoluminal USS staging, and
efficient chemotherapy. We used a prospective database to identify
patients with PGL (defined according to criteria by Lewin and
Herrmann) treated at the RMH since 1985 with surgery followed by
chemotherapy (n= 13) or chemotherapy alone (n=25). A larger
proportion of patients in the chemotherapy alone group had
anorexia, abdominal pain, a palpable epigastric mass or GI bleeding at
presentation. Equally, more patients had advanced disease on
Mushoff staging. All lymphoma-related deaths occurred in the first
year following diagnosis. Overall survival was identical in the surgery
plus chemotherapy and the chemotherapy alone group, ( 87.6 vs. 84.6
%), and the major determinator of outcome was stage at diagnosis (
Stage IE and IIE1 100% 5 y survival, more advanced stages 76 % 5 y
survival). 3 of 13 patients developed malabsorption after
gastrectomy, while 5/25 patients receiving chemotherapy alone had
GI bleeding. 2 patients had extensive inoperable tumors invading the
whole gastric wall, and 1 patient had recurrent bleeding and
underwent gastrectomy. No perforations took place. In this series,
chemotherapy alone was as efficient as the combination of surgery
and chemotherapy in intermediate and high-grade PGL of any stage,
and no perforations or serious bleeding occurred.
P037 OESOPHAGEAL STENT INSERTION FOR
INOPERABLE CA OESOPHAGUS. IS IT OF VALUE?
Aitobinsonl, A.Solieri2, J.O'Brien3, G.Bray4, C.Trask5,
A.Lamont6, WDept. Oncology, 2Audit, 4 Dept. Gastroenterology,
Southend Hospital, Prittlewell Chase, Westcliff, Essex, SSO ORY
Retrospective review ofoesophageal stent insertions from01.08.95
- 31.12.96 was carried out. Objectives:
1 Are patients selected appropriately?
(Defined survival >2/12)
2 Is reliefofdysphagia achieved?
3 Are Dietitian and Macmillan services enlisted?
4 Is information about procedure given?
19 patients, histologically proven (47.3% Adeno., 47.3% SCC and
5.3% Small Cell) with inoperable Ca oesophagus, were stented
using covered oesophageal stents. 57.9% female, mean age 70.4
years. All had significant weight loss (10% bodyweight) and 20%
total dysphagia at time ofprocedure. Procedure was well
tolerated, one (5.2%) complication - cardiac arrest (patient
successfillly resuscitated, subsequentlyunderwent stenting).
52.6% received additional XRT, 10.5% chemotherapy and 36.8%
no fiurther treatment. 63.1% survived >2 months post procedure,
mean survival 7 months, all tolerated semi-liquid to normal diet up
to death. 80% and 74% had Dietitian and Macmillan nurse
involvement respectively. An information leaflet was given to 74%
patients.
Conclusions: Stenting achieved significant palliation. Now
standard procedure to refer patients to Dietitian, multidisciplinary
meetings ensure access to Macmillan nurse when appropriate.
P039 HEPATIC ARTERIAL FLOXURIDINE IN SYSTEMIC 5FU/ FOLINIC
ACID RESISTANT COLORECTAL LIVER METASTASES, C. Fordy, C.
Glover, K. Handscomb, M. Davies, T.G. Allen-Mersh. Dept. of Surge,y, Charing Cross and Westminster
Medical School, Chelsea and Westminstir Hospital, London, SW10 9NH.
The management ofcolorectal liver metastasis patients (CLM) who
have failed to respond to systemic 5 Fluorouracil (5FU) / Folinic Acid
is unclear. Hepatic arterial infusion (HAI) ofFloxuridine (FUDR) has
been reported as producing tumour response in comparative studies
where non-responsive systemic patients were "crossed over" to HAI.
We have assessed response and response duration in 33 patients
(median tumour volume 322 mIs, IQR 55 mIs, 736.75 mls) with CLM
progression on systemic chemotherapy treated with a median of6
cycles ofcontinuous HAI Floxuridine 0.2mgs / kg /24 hours over 14
days.
Partial response (>50% tumour shrinkage) occurred in 3 (10%) and
disease stabilisation (any tumour shrinkage) in a further 4 patients.
Duration ofdisease stabilisation (interval to metastasis regrowth
above baseline CT scan) was 9.5 months. Fall in serum CEA occurred
in 22 (67%) patients, the duration ofserum CEA fall-was a median of
6 months (IQR 4.25, 12).
193 treatment courses were delivered and 48 treatments were omitted
because oftoxicity. WHO grade 1 or 2 toxicity (nausea / vomiting,
stomatitis, gastritis or diarrhoea) occurred in 11(33%) and reached
grade 3 or 4 in 10 (30%) patients.
HAI Floxuridine in systemic 5FU resistant patients stabilised liver
metastases in 21% ofpatients for 6 - 9 months. The results are similar
to other reported second line chemotherapy regimens in advanced
colorectal cancer. HAI may offer benefit to selected CLM patients
with systemic 5FU resistant disease.Poster Presentations 49
P040 INTRA-LUMINAL BRACHYTHERAPY FOR
CHOLANGIOCARCINOMA USING THE NEW
ULTRAFLEXIBLE 'MICROSELECTRON-HDR V2` OBLITERATES THE NEED
FOR AFTERLOADED IRIDIUM. P.B. Rogers', A.J. VinalI2, J. Solano',
A. Hatfield3, M.F. Spitte'. Departments of 'Clinical Oncology, 2Medical Physics
and 3Gastroenterology, Middlesex Hospital, London WlN 8M, UK.
INTRODUCTION: The Middlesex Hospital is a clinical trial site for the new
microSelectron-HDR V2, made by Nucletron. Since 1989 we have tried to use
the "ClassicmicroSe/ecfon"in 40 patients to give intra-luminal brachytherapy
via a nasobiliary tube placed at ERCP. The cable has only been flexible
enough to treat one patient. The source was unable to pass the acute
duodeno-choledochal angle (DCA) in 98% patients who therefore required
treatment with manually afterloaded Iridium, necessitatng admission for one
week to undergo ERCP and brachytherapy over 2-3 days in the radiabon
protecton room. Patients also received external beam radiotherapy.
OBJECTIVE: To assess whether the new microSe/ectron-HDR V2 can
negotate the most acute DCA to treat inoperable cholangiocarcinoma.
METHOD: The microSelectron-HDR V2, with a 20% smaller source size
(0.9mm diameter) and more flexible cable, was tested on 2 patients with acute
DCA's. During ERCP the 1.5m microselectron catheter was placed in positfon.
A dummy source was used to assess feasibility prior to treatng the patient.
RESULT: The dummy source made three clear test passes. The remote
afterloadina high dose rate Iridium source was therefore used to treat the
cholangiocarcinoma. A dose of 18 Gy to 0.5 cm was given over 3 minutes and
19 seconds, thereby treating a patent who would otherwise have required
treatmentwith a manually afterloaded source as an inpatent over 3 days.
CONCLUSIONS: The new machine has important advantages:
1. It will eliminate the need for inpatent care in the radiabon protecton room,
allowing the patent home on the same day.
2. Itwill decrease radiation exposure to physicists, doctors using the manually
aftedoaded Iridium, nursing staff and visitors.
3. Itwill allow the radiation protection room to be used for other treatments
thereby decreasing waitingbmes.
4. Itsaves the cost ofthe use ofa bed for one week.
P042 SUOG/SCTN NATIONAL SCOTTISH PROSTATE CANCER AUDIT, Windsor PM', Thomson CS2,
Stroner PL3, Goodman C4. Department of Radiotherapy, Ninewells
Hospital, DuMdee DDI 9SY, 2 Scottish Cancer Intelligence Unit, ISD
Scotland, Trnity Park House, South Trinity Road, Edinburgh EH5 3SQ,
Scottish Cancer Therapy Network, ISD Scotland, Trinity Park House,
South Trinity Road, Edinburgh EH5 3SQ, 4 Department of Urology,
Dundee Royal Infirmary, Dundee.
All men newly diagnosed as havig prostate cancer were identified fim
the Scottish Cancer Registry, 1221 men in 1988 and 1591 men in 1993.
Hospital records were accessed by Scottish Cancer Therapy Network data
managers and an audit data set extracted, 91% of notes were accessed.
Tumour staging was often poorly documented or omitted. Staging bone
scans were carried out in only 43% of patients in 1988 rising to 58% in
1993, with an increase in negative scans. There was a nse m radical
radiotherapy from 67 (5.5%) in 1988 to 134 (8.4%) in 1993; this showed a
marked regional vaniation, most referrals (74% and 64%) were by
urologists. Most patients having radical radiotherapy had undergone
TURP (76% and 66%), the use ofbiopsy increased (21% rising to 33% in
1993). Overall only 5.8% of patients in 1988 and 10.4% in 1993 had
radical (curative) treatment by radiotherapy or radical prosatectmy. As a
percentage of docwnented MO patients (244 and 479 respectively) this
amounted to only29% in 1988 rising to 34% i. 1993.
P041 A PHASE 11 STUDY OF INTERFERON alpha-2a (IFNa) AND MODULATED 5-FLUOROURACIL
(5-FU) IN PATIENTS (pts) WITH ADVANCED
NEUROENDOCRINE TUMOURS (NET). D.Papamichael, R.T.Penson,
M.T.Seymour, P.Wilson, C.J.Gallagher, G.M.Besser, M.L.Slevin.
Background: Both 5FU and IFNca have shown modest single
agent activity in pts with NET, with biochemical responses much
more common than objective responses. The combination of 5FU
and IFNa has shown synergy in tumour models, and activity in
several gastrointestinal malignancies.
Methods: Fifteen pts with advanced NET (12 carcinoid, 2 islet
cell, 1 phaeochromocytoma) of whom 3 were non-secretors,
were treated with leucovorin 200mg/M2 intravenous(i.v.) infusion
over 2 hours, then 5FU 400mg/M2 i.v. bolus followed by 400mg/mi2 i.v. infusion over 22 hours, all repeated on day 2; IFNa
was given at 6 x 106 U subcutaneously evey 48 hours
throughout. Treatment was given every 2 weeks for up to 12
cycles. In case of stable disease (SD) or partial response (PR),
IFNa was continued until disease progression (PD). All pts were
chemotherapy naive; one pt had prior treatment with 1311_
metaiodobenzylguanidine.
Results: Patients received a median of 5 courses (range 1-12).
Two pts (one carcinoid, one islet cell) achieved a PR (13%; 95%
confidence interval 2-40%), of 3 and 4 months duration. Five pts
(all carcinoid) achieved SD (33%) with symptomatic response, for
a median of 8 months (range, 4-22 months). Both pts who
achieved PR and 3/5 with SD had a> 50% marker reduction (5-
HIAA, VIP). Four pts had PD. Another 4 were not assessable or
response due to early toxicity necessitating cessation of
treatment. Two had grade III-IV diarrhoea and 2 grade IV
neutropenia requiring i.v. antibiotics. Four patients required a
50% dose reduction of the IFNa for fatigue.
Conclusions: These results suggest no clear advantage for the
combination of 5FU and IFNcx over the individual agents alone;
the combination may also result in increased toxicity and reduced
tolerance.
P043
PACLITAXEL, VINBLASTINE, CISPLATIN (PVC) IN
PATIENTS WITH ADVANCED TRANSITIONAL CELL
CANCER (TCC) B McLaren', CJ Gallagher', M Mason2, G
Melesi', RTD Oliver', Depts ofMedical Oncology, St
Bartholomew's Hospital', London and Clinical Oncology, Velindre
Hospital2, Cardiff, United Kingdom.
Cisplatin based combination chemotherapy is standard treatment for
pts with TCC however paclitaxel has been shown to have significant
single agent activity (ASCO;1994 704). This study was initiated to
pilot these two active agents combined with vinblastine.Eligibility
criteria were advanced TCC, Kamofsky score >60, no prior
systemic chemotherapy, adequate haematologic/ renal function.
Treatment was paclitaxel 175mg/M2 over 3 hr, cisplatin 70mg/M2
day 1, vinblastine 3mg/M2 days1 and 8 repeated every 21 days with
premed, dexamethasone, chlorpheniramine, cimetidine. Vinblastine
was omitted on day 8 iftotal neutrophil count <1.0. Fifteenpts
were treated (13M, 2F).Median age was 66(54-75). Six had had
radical tumour resection, eight transurethral tumour resection and
one was inoperable. Five had received bladder radiotherapy Sites of
disease; lymph nodes(l0), bladder(6), lung(5), liver(3), pelvic
mass(2), bone(2), ureter(1) and prostate(l). A median of 5 cycles
was given (1-6) with 2 (13%) pts achieving CR and 5 (33%) PR.
Overall response rate 47% (95% CI 22-72%). 3 pts had SD, 4 PD
and1 early death due to bowel obstruction. All responses were in
locally recurrent tumour and/or lymph nodes. Grade III/IV
neutropenia was observed in 14/67 cycles and 7 episodes of
neutropenic fever occurred. Other grade III toxicity; alopecia(lOpts)
diarrhoea(2), constipation consistent with bowel obstruction(2),
peripheral neuropathy(1), pain secondary to myalgia(l) and
nephrotoxicity(l). Six patients had grade II paraesthesiae.Median
time to progression was 6 mths. PVC is active in advanced TCC,
with.manageable toxicity.A future study is planned of MVAC vs
MVPC substituting paclitaxel for doxorubicin.50 Poster Presentations
P044 BONE SCINTIGRAPHY IN PATIENTS WITH
CARCINOMA OF THE BLADDER REFERRED FOR
RADICAL RADIOTHERAPY,
A.N.J Tutt, G.Jay, D.P.Dearnaley, Urological Oncology Unit, Royal
Marsden Hospital, Sutton, SM2 5PT.
Purpose: To assess the value of a selective policy of use of scintigraphic
bone scan (SBS) in patients referred for radical radiotherapy for
transitional cell carcinoma (TCC) of the bladder.
Method: A retrospective review of 323 patients referred to our unit
between January 1991 and August 1994 revealed 101 on whom SBSs
had been performed based on the prospectively defined criteria of either,
symptoms compatible with bone metastases or elevation of serum
alkaline phosphatase (AP). Following independent review of the SBSs
by a nuclear medicine radiologist, apossible correlation between positive
SBS and raised AP was sought using a 2x2 table and chi squared
analysis.
Results: Serum AP was elevated in 26% of those patients who had SBS.
An SBS diagnosis of bone metastasis was made in 26% of patients on
whom SBS was performed. An elevated serum AP was associated with a
positive SBS in 50% . A normal serum AP was associated with an
abnormal SBS inonly 16%(X2=16.4,p<0.0001). Bone metastases were
foundpredominantly distributed in the axial skeleton with no predilection
for the lumbar spine or pelvis. Three patients with apparently solitary
pelvic bone metasasis, who were treated radically, relapsed with multiple
bone metastases within four months ofcompleting treatment.
Conclusion: The selective use of SBSs, in patients being considered for
radical treatment for muscle invasive TCC bladder, diagnosed bone
metastasis in a quarter of those tested. The detection of an apparently
solitary deposit should not influence the decision to treat such patients
palliatively.
P046 CCOMPARATIVE TOXICITY OF VP 16-2 1 3 IFOSFAMIDE
AND CISPLATIN (VIP) PLUS HIGH DOSE VERSES TAXOL
IFOSFAMIDE CISPLATIN (TIP) PLUS HIGH DOSE IN
SEQUENTIAL PHASE 1/2 STUDIES. CA O'Doherty, S Asterling, J Ong, CJ
Gallagher, RTD Oliver. Medical Oncology, St Bartholomew's Hospital, London ECIA
Currently three courses of VIP plus a single high dose treatment wvith
peripheral blood stem cell rescue is the experimental arm in a pan European
randomised trial against 4 courses of VIP as first line salvage therapy for germ
cell cancer patients failing BEP therapy. Prompted by reports that Taxol had
activity in germ cell cancer patients we have set up a study investigating the
effects ofsubstituting Taxol 21Omg/m2x1 for Bp 16-213 125mg/M2 dl-3 in the
induction protocol. This abstract reviews the comparative ofour sequential
phase 2 experience ofthese two regimens. A total of22 patienits have been
induced with VIP and 17 with TIP. Six in each study did not procede to high
dose, either because they were drug resistant, or had chemo responsive disease
with residual mass that was sufficiently localised for surgery. Twventy seven
patients proceeded to high dose procedure, there were two major episodes.
One of these was renal failure on requiring dialysis after VIP and the second
was bowel necrosis-after TIP. Apart from this there were no treatment related
mortality or morbidity. There were no significant differences in time to
neutrophil orplatelet recovery or time to discharge. 7 of 16(44%) of VIP+HD
remain relapse free for more than 22 months, while 9 of I I (82%) withTIP
remain progression free after a median of 6 months. It is conicluded that it is
possible to substitute Taxol 210mg/m2 for Etoposide in the VIP plis hligh dose
regiment without producing any major increase in toxicity and that responses
at this stage seem to be at least equivalent to those achievable withVIP and
thlat furtherstudy ofthis approach is justified.
P045 APHASEIISTUDYOF SUBCUTANEOUS (SC) INTERLEUKIN-2 (IL-2), ALPHAINTERFERON
(IFN) AND PROLONGED VENOUS INFUSIONAL (PVI) 5-FU IN
PATIENTS WITH METASTATIC RENAL CELL CANCER MM
Vaughan, SRD Johnston, JS Moore, ME Gore, Royal Marsden Hospital,
FulhamRoad, London SW3 6JJ
Biochemotherapy regimens which combine IFN, IL-2 and bolus 5-FU have
beenreportedtohave responseratesof>400/oin patientswith renal cell cancer
(Aztipodean etal. 1993). PVI 5FU has been shown to have advantages over
bolus administration. Inthisstudy weassessedtheefficacy andtoxicity ofPVI
5-FU with SC IL-2 and IFN. Twenty one patients with metastatic renal cell
cancer weretreatedwithSCIL-2( MIU/m2 bddays 3, 4and5ofweeks I
and 4; and5MIU/m2 days 1, 3 and5 ofweeks 2 and 3), SCIFN(6MIU/m2
day1 ofweeks1 and4,anddays1,3and5ofweeks2and3;and9MIU/m2
days 1, 3 and 5 ofweeks 5-8) and PVI 5-FU (200 mg/in/day weeks 5-9).
Patientswith anobjective response(CR/PR) ordisease stabilisation weregiven
a further 9 week cycleprovidedthat toxicity was acceptable. Eight of 21
patientshad apartial response inmeasurable sites ofdisease (38%, 95%CI 18-
62),andthere were afurther2patientsinwhomdisease was stable for at least 4
months. Fivepatientsreceivedlessthan 3 weekstreatment; 2 withdrew because
oftoxicity and 3 becauseofearly diseaseprogression. Theoverall mediantime
todiseaseprogressionwas16weeks (range1 to46), butthishasnotyetbeen
reached inresponding patients.All patients experienced grade 2constitutional
symptoms, and 5patients sufferedgrade Im toxicity(rash, 2 pts; hypotension, I
pt; renal failure,1 pt; confusion,1 pt), this was reversible in all patients. In
conclusion, IL-2,IFNandPVI 5FUis apromising andactivebiochemotherapy regimeninmetastatic renal cell cancer.
Reference:
Aztipodean Jetal. Interleukin-2 incombination with interferon alpha and5-Fluoroisacil for melastaticrenal
cell cancer. EurJCancer 1993; 29A(Supp5):S6-8.
P047 MALIGNANT SUPRATENTORIAL GLIOMAS IN CHILDHOOD:
THE GREAT ORMOND STREETEXPERIENCE.
N. Shah',K. Phippe', A.Michalski'2, W. Harkneas, R.Hayward and
M. Gaze'2. 'TheMiddlesex Hospital and The Great Ood Stet Hopita forChildren (GOSH), London.
Introduction High grade supratentorial gliomas in children account
for 7-11%ofprimarybrainneoplasms. Unliketheiradult counterparts,
longer survival is noted following standard treatment. This
retrospective study analyses survival in relation to patient and tumour
related factors, and treatment techniques in children referred to the
GOSH from 1980-1995.
Method 52 patients with histologically proven high grade
supratentorialgliomas were reviewed. The median age ofpresentation
was 7.25 years (range 2 months-15.75 years) with a male to female
ratio of30:22. The ratio ofGrade 3 to Grade 4 tumours was 22:30.
Thetablesumnmrisesthe various treatmentsemployed.
Primarytreatment Surgery RT CT + RT CT
OpenBiopsy 4 3 0 0
Steretactic Biopsy 6 5 0 0
Incomplete resection 36 27 3 2
Gross resection 6 3 1
RT= Radiotherapy, CT=Chemotherapy,
Results Overallmedian survival fromthetime ofhistological diagnosis
was 29 months (range 0-14.4 years).The proportion ofpatients alive at
2 and 5 years following treatment were 52% (95% CI 37-67%)and
37% (95%CI20-54%) respectively. Improved survival was not noted
withthe extent ofresection(p=0.39), radiotherapy (p=0.48), grade of
tumour(p=0.86) or age ofthe patient(p=0.27).
Conclusions In our series, the median survival is comparable to the
published literature assessing childhood gliomas. In contrast, we have
not observed a survival benefit with macroscopic resection of the
tumour or post operative radiotherapy.Poster Presentations 51
P048 POSTERIOR FOSSA BOOST IN MEDULLOBLASTOMA -
A COMPARISON OF STANDARD FIELD AND THOSE
PLANNED FROM THE PRE-OPERATIVE MRI SCAN
I D Pedley, R E Taylor, 0 E Gerrard - Yorkshire Regional Centre for Cancer
Treatnent, Cookridge Hospital, Leeds, West Yorkshire
Introduction: Craniospinal radiotherapy followed by a posterior fossa boost is
the routine management for medulloblastoma. The standard posterior fossa field
in the current SIOP PNET 3 Study is delineated by the posterior clinoids
anteriorly, the inner table ofthe skull posteriorly, the C2/C3 interspace inferiorly
and superiorly lcm above the midpoint between the foramen magnum and the
vertex. The object of this study was to investigate whether adopting ICRU 50
guidelines with the pre-op MRI images would alter the posterior fossa field size.
Methods: For 17 patients with medulloblastoma the gross tumour volume
(GTV) was marked on the orthogonal film as defined by the T2 weighted image.
Using a 2cm margin and applying the ICRU 50 guidelines the field size was
obtained and compared to the standard.
Results: In 13 patients the field sizes were identical. For 3 patients the MRI
derived fields were smaller than the standard and in all cases this was due to the
inferior margin. The mean difference was 8mm (range 6 to 10mm). In the one
other patient the MRI derived field was larger by 9mm due to the inferior
margin.
Conclusion: In the majority of cases the posterior fossa field is delineated by
the standard field. However it is recommended that in all cases the pre-
operative MRI scans be studied to ensure adequate coverage of the GTV and
also to exclude the possibility ofusing smaller fields.
P050 BENIGN MENINGIOMA OF THE SKULL BASE.
C Nutting, L Brazil, A Sibtain, J Steele, H Alheit,
D Traish, S Ashley, M Brada. Neuro-oncology Unit & Academic Unit of
Radiotherapy & Oncology, Institute of Cancer Research & Royal Marsden
NHS Trust, Sutton SM2 SPT, UK
Purpose: To assess the long-term results of conservative
surgery and conventional external beam radiotherapy (RT) in
the management of skull base meningioma, particularly as a
baseline to help in the evaluation of new treatment strategies.
Patients and methods: A retrospective review of 82 patients
treated at the Royal Marsden Hospital for benign meningioma
of skull base between 1962-1992.
Results: 82 patients aged 13-74 (median 50) years with benign
skull base meningioma were treated with conservative surgery
and radiotherapy. 62 patients received RT after initial
diagnosis and 20 after tumour recurrence. 33 patients had
sphenoid ridge, 26 suprasellar and 23 other skull base tumours.
Initially 73 patients had subtotal excision or biopsy and 9
complete excision. The usual radiotherapy was 50-55 Gy in 33
fractions (median 50.8 in 33 F). 10 year progression free
survival (PFS) was 83% with site of disease, the only
independent prognostic factor on multivariate analysis.
Tumours of the sphenoid ridge had significantly worse disease
control than other sites (69% vs 90-100% 10 years PFS). 10 year
survival was 71% with PS (+age) the only significant
prognostic factor.
Conclusion: Although the efficacy of RT in the treatment of
incompletely excised benign meningioma remains unproven,
the majority of patients achieve excellent long-term tumour
control, particularly young patients with good PS, and
tumours outside the sphenoid. The results can be used as a
baseline for the evaluation of new treatment strategies. W e
are now evaluating stereotactic RT in this settin'g and have
P049 A COMPARISON OF TREATMENT VOLUMES PLANNED
USING CT AND MRI IMAGING IN THE TREATMENT OF
CEREBRAL GLIOMAS. G.E. Gerrard, R.E. Taylor, M.P.
Collinson, I.D. Pedley, J. Povall. Dept. Of Clinical Oncology, Cookridge Hospital,
Leeds, West Yorkshire.
The object ofthis study was to compare the treatment volumes planned using MRI
imaging with those obtained using CT scans.
Materials and methods: The study involved twenty patients with cerebral gliomas
twelve low grade and eight high grade gliomas] who received radical radiotherapy at
either Cookridge hospital, Leeds or Weston Park hospital, Sheffield between June
1995 and December 1996. The pre-operative gross tumour volume [GTV1 was
marked on the orthogonal antero-posterior and lateral radiographs, using initially the
CT images then the MRI information. The contrast enhancing edge on CT was used
to define the GTV [or the hypodense area ifnon-enhancing]. With MRI images the
enhancing edge with gadolinium was used to define the GTV [or the T2-weighted
image ifthere was no enhancement]. The target volume was then marked and a
treatment plan produced. Field sizes were taken from the mid-plane ofthe plan and
the irradiated volume calculated [as defined by 50%/o ofthe intersection dose].
Results: In twelve patients the CT and MRI volumes were identical. In six patients the
MRI volume was larger than the CT volume, with an average size difference of 105
cm3 [ range 68 to 145 cm31. However the field sizes were only 0.5 to 1.0 cm larger
in one or two dimensions. Thesepatients had little or no enhancement with
gadolinium. Smaller volumes with MRI imaging were found with two patients with
low grade gliomas which were hypodense on CT scanning, and did not enhance
following contrast with either CT or MRI. In these two cases the MRI volumes were
241cm3 and 270 cm3 smaller than the CT volumes, corresponding to a 0.5to 2 cm
smaller field sizes in two dimensions. For all twenty patients the MRI derived mean
irradiated volume was 1412 cm3 [range 319 to 2561cm, 95% confidence interval +/-
303 cm3J, and the CT derived mean irradiated volume was 1405 cm3 [ range 319to
2760 cm3, 95% confidence interval of +/-298 cm31.
Conclusions: Since in the majority of patients [60%l the two volumes were identical
there seems no need to routinely use different margins with MRI and CT imaging. In
the cases [300/oJ in which the MRI volumes were greater, the resulting field sizes were
only 0.5-1.0 cm in 1-2 dimensions. MRI was foundtobe preferable in low grade
tumours which showed no enhancement on CT and resulted in smaller irradiated
volumes.
P051 THE VEDEX REGIMEN: AN EFFECTIVE
AND WELLTOLERATED PALLIATIVE
TREATMENT FOR RELAPSED NON-
HODGKIN'S LYMPHOMA (NHL). L El-Helw, PC Lorigan, RE
Coleman and BW Hancock. YCRC Department of Clinical Oncology,
Weston Park Hospital, Sheffield, S10 2SJ, UK.
We have evaluated the efficacy and toxicity of a novel weekly
intravenous palliative chemotherapy regimen with vincristine lmg,
epirubicin 30mg/m2 and dexamethasone 20mg (VEDex) in relapsed
NHL. This was a retrospective study of 49 consecutive patients treated
at Weston Park Hospital. The median age was 68 years with a range
of 34to88 years. 17 patients (34.7%) had low grade disease resistant
to conventional alkylating therapy and 3 patients (6.1%) had
transformed (initially low grade) NHL. 29 (59.2%) had relapsed high
grade NHL; of these 22 had poor performance status which precluded
high dose chemotherapy and 7 were heavily pretreated. Responding
patients received up to a maximum of 8 cycles of treatment but this
could be repeated at a later stage if required. The overall response rate
was 67.3%, 10 patients (20.4%) achieved complete and 23 (46.9%)
partial response. A further 16 patients (32.7%) had stable disease. 23
patients (46.9%) reported complete resolution of symptoms and 15
(30.6%) had partial resolution of symptoms. Grade III neutropenia
was seen in 7 patients (14.3%) and grade IV in 1 (2%). Other relevant
toxicities included nausea and vomiting grade III (4.1%) and alopecia
grade III (2%). Peripheral neuropathy of greater than grade I was not
reported. The median survival from start of treatment was 6 months.
No patients died of treatment related toxicity. VEDex is an effective
and well tolerated palliative treatment for patients with relapsed NHL
who are elderly or have a poor performance status and/or who are
heavily pre treated.
treatwd 17 patients in the last year.52 Poster Presentations
P052 PRIMARY INTRACEREBRAL LYMPHOMA: A
CLINICAL STUDY OF 22 PATIENTS. R.E.Hough,
M.H. Robinson, P. Lorigan, B.W.Hancock. YCRC
Department of Clinical Oncology, Weston Park Hospital, Sheffield.
Primary intracerebral lymphoma is an uncommon presenting
site for non-Hodgkin's lymphoma. The authors review 22
histopathologically confirmed, consecutive cases presenting over a
15 year period between January 1982 and January 1997.
The cohort included 16 males and 6 females with a mean age
at diagnosis of 55.0 years (range 27-75 years). 2 patients were
taking immunosuppressive therapy following renal transplantation.
Presenting symptoms included personality change and confusion
(50%), headache (40%), limb weakness (30%), seizures (20%) and
visual disturbance (20%). The mean time from onset of these
symptoms to diagnostic biopsy was 8.5 weeks. Subtotal resection
was performed in 5 patients. Radical whole brain irradiation was
given to 20 patients; 2 received additional radiation to the tumour
site. 2 patients were too unwell to receive treatment and
subsequently died. 3 patients also had chemotherapy. Clinical
remission was achieved in 14 patients. Of these, 7 relapsed after a
median time of 10 months - 4 received palliative chemotherapy and
1 of these attained a further remission. 8 patients (36% total cohort)
are still alive and in remission after a median period of2 years and 8
months (range 6 months to 10 years and 10 months). Cause of
death was intracerebral lymphoma in11 ofthe 14 patients who died,
pulmonary embolus in 2 and bronchopneumonia in 1. Median
survival was 5 months in this group.
Primary intracerebral lymphoma is a rare tumour associated
with poor prognosis. However, durable remission can be achieved
with radical treatment (primarily radiotherapy) at presentation.
P054 IVE SALVAGE CHEMOTHERAPY AND MOBILISATION
OFPERIPERALBLOOD STEMCELLS (PBSC) FOR
RELAPSED HODGKIN'S AND NON-HODGKIN'S LYMPHOMA. L.K.
Dawson(l), J. Craig(2), D.A.Cameron (1), F. Forrest (1), andRC. F. Leonard(l).
(1) Dept. ofClinical Oncology, Western General Hospital, Edinburgh, EH4 2XU.
(2) BloodTransfusion Service, Royal Infirmary, Edinburgh.
Salvagc therapy in lymphoma comprises avariety ofregimens with the
intention ofnot only achieving further diseasecontrol but potentially to provide an
opportunity to harvest stemcellsfor subsequenttreatment intensification to
consolidate the response obtained The IVE regime ( Ifosfamide 3gtm2 days 1-3;
EpirubicinS0mg/m2 dayI and Etoposide 200mg/2 days 1-3 ) inconjunction with
G-CSF was given foramaximum of3 cycles in 11 patients aged 20-70 years.
Ofthe 11 patients treated from 1994-1997,2 had nodular sclerosing
Hodgkin's disease (HD); 9 had intermediate and high grade non-Hodgkin's
lymphoma (NHL). All had hada minimum ofone previous chemotherapy regimen
andat best hadachieveda partial response to therapy.
Thetrcatment was tolerated reasonably well by all ; only I patient had
problems with Ifosfamide induced encephalopathy; 8 patients required inpatient
trcatment for neutropenic sepsis with 3 patients requiring either discontinuation or
modification oftherapy; 4 patients did not require bloodproduct supportduring
treatment.
Successful mobilisation of PBSC wasobtained in all 9patients considered
forfurther high dosechemotherapy. 5 patients havebeen treated andsuccessfully
engrafted, I ispatient currently starting treatment following re-inductionafter
aggressive relapse and I patient is underassessment. The other 2 patients were not
felt tobe suitable forconsolidation high dose treatment.
P053 PRIMARY NON HODGKINS LYMPHOMA OF
BONE - TREATMENT AND OUTCOME
S Sothi and D Spooner Royal Orthopaedic Hospital and
Queen Elizabeth Hospital, Birmingham, U.K.
Primary non Hodgkins lymphoma of bone is uncommon.
Between 1985 and 1996, 32 patients presenting with primary
bone lymphoma were treated at our centre. Diagnosis was
confirmed histologically in all patients. 29 patients had high
grade lymphoma, 3 low grade. 31 had B cell tumours, one T
cell. Mean age of patients was 48 years (range 5 to 89 years).
19 patients (56 %) presented with disease localised to a
solitary bone (Stage IE), 2 patients had solitary bone disease
with regional nodes (StageIIE) and 10 patients had Stage IV
disease. One patient had recurrent disease. Of the Stage IV
disease, 4 had multifocal bone disease, 2 had distant nodal
disease and 4 had other extranodal sites of involvement. 18
patients had long bone tumours, 14 had axial tumours.
25 patients were treated with chemotherapy (standard CHOP
regime) followed by local radiotherapy. 3 patients had surgery
as their local treatment (endoprosthetic replacements,
fibulectomy) and chemotherapy. 2 patients had chemotherapy
alone ( both children ). 2 patients had surgery (spinal
decompression), chemotherapy and radiotherapy.
29 cases completed the prescribed treatment and are
evaluable for response. All Stage IE patients who completed
chemotherapy and radiotherapy achieved complete remission
with no evidence of local recurrence (mean follow up of 46
months, range 6 to 133 months). Of the Stage I patients, 1 out
of 19 developed systemic disease (low grade). Of the Stage IV
patients, 2 out of 10 died of progressive lymphoma. Five year
survival using the Kaplan Meier survival analysis was 84 %
forStage IE patients and 42% for Stage IV patients.
The addition of chemotherapy to local treatment for primary
lymphoma of bone has improved outcome.
P055 ACQUIRED IMMUNODEFICIENCY SYNDROME
(AIDS) - RELATED PRIMARY CEREBRAL
LYMPHOMA: RESPONSE TO IRRADIATION. V.S. Khoo', K. H. Liew2
and M. Sexton2. 'Academic Unit of Radiotherapy, Royal Marsden NHS
Trust, Sutton, Surrey SM2 5PT,2Dept. of Radiotherapy, Peter MacCallum
Cancer Institute, East Melboume, Australia 3002.
Aim and methods: Fourteen cases of AIDS-related primary cerebral
lymphoma (APCL) were retrospectively reviewed between 1986 and 1994 to
characterisethenaturalhistory and response ofthesepatients to radiotherapy
(RT). Results: The median age was 38 years (range 24-65). The median
interval between sero-positive diagnosis of the human immunodeficiency
virus (HIV) and APCL was 28 months (range 5-113). The median duration
of symptoms prior to presentation was 2 weeks (range 0.2-12). At
presentation, 12/14 patients were ECOG performance status 2 or 3. The
symptoms and signs were non specific. There was no consistent specific
pattem of brain imaging in terms of size, number, location or pattem of
contrast enhancement ofthe cerebral lesions. Nine patients were selected for
RT based on their performance status and received varying fractionation
schedules (2000-5000cGy). The response rate was 89% (8/9) with either
improvement or stabilisation in neurological symptoms or performance
status. Unfortunately the response duration was short with a median survival
time (MST)post-RT of 5 weeks (range 0.6-37). The MST from presentation
at our institution for treated and untreated patients were 8.5 and 2 weeks
respectively (range 0.9-43) (p=0.004). Conclusion: The optimum
management for APCL remains undefined. Although patient selection
introduced bias and influenced the outcome, there appears to be a modest
improvement in MST for treated patients. The survival results using RT
alone for A-PCL remains poor but RT may provide substantial palliation.
For some selectedpatients, aprolonged response is possible.Poster Presentations 53
P056 HIGH-DOSECHEMOTH-ERAPYAND
AUTOLOGOUS STEM CTELL TRANSPLANT-
ATION IN 3 PATIETS WIT LYMPHOMATOUS POLYPOSIS R A.
PopescuandD. GC ingan lTmen"tiqfMJca Oncooy, 7heRuilMair&n
AISTmz4&a^onm&ey
Lymphomatus polyposis P) is a ramr, diinctive tpe of prinary Bel
o n (G) u ympho darerised by mliple polyps affeci various
parts ofthe GItrac, andthoughtto be milaringotype,photype anlinicl
behaviour to rodal mantie cel lynphoma (MCL). The dasscl hiatolol
appearance is of nall eaved cenroctes anged in a rndular patemofvariable
dgree,whi areCD20+, CD5+, COD ,CD10-, CD3-. Despitebeingdssifieas
a lowlrade lymphoma, LP has a poor response to chenotherapy (mnduding
aridin cniing egimens),with hoItrmissionsandmedianoverall rvivaL
Ongoing dceodhrapy trials for MCL atmp to maxmise response rates and
durationbydinorapydoseitensin ction. Wereportourexperierewithhig
dosetremnin3maepats withLP. 2paathadiunorcolonresecionsat
All patie chived rmission (2CR, 1PR) following Conventional
dhemoteapy (2 CHOP, 1 Pacbom), lainng 4-16 months. They reapsed
systernia and reaived salva chemotheapy (EPIQ DHAP, CHOP). Two
patient rnedaPR,andoneanearCR Highdose hemothrapyandstemcel
resuewasgven,followingwhch all 3wentintoCR Onepaentreapsed7mornts
laterinthespleen,whi wasimvolved, as washisbone manow, atfirstreapse He
responded poorly to 4 farthe line of rtnt, an diced 23 montis following
tnslan T twootherpatsremainwellandinCR6and54monthsfollowing
trwsplant. High k secherothrapyandautologoustransplanionforLPis fasible
andmayrducelongremisionsinadiaseconvemonallydto tobeicurable,n
analogy to foUalar bmphoma where stong evidex for tis has amteL
Further stuies are neeJ to d ine efficay and role ofhighdosetheapy and
autologoussiportinthe oflymphomats poposis.
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P057 VARIATION IN SPINAL CORD DOSE IN PATIENTS
RECEIVING PALLIATIVE RADIOTHERAPY FOR
LUNG CANCER D.Bottomley, A Morgan, D Sebag-
Monteffore, E McVey, HProbst, D DodwelL Yorkshire Centre for Cancer
Treatment,Cookridge Hospital, Leeds.
Introduction The publication ofthe MRC LU08' trial has ledto the widespread
use ofa fractionation of 17 Gy in 2 fractions one week apart for patients with
inoperable lung cancer. The radiobiological analysis ofthe three reportedcases of
radiation myelitits in the MRC trials2 was basedon the assumption thatthe
average dose to the cord might be 5% greater than midplane andrecommends that
ifthethoracic spinal corddose exceeds a linear quadratic equivalent dose
(LQED2) of48 Gy that methods to reduce the corddose shouldbe considered. A
pilot study was therefore designed to assess the variations that exist in the
maximum spinal corddoses depending on patient separation and machine energy.
Methods Fifteen patients with inoperable lungcancerwho received 17 Gy in 2
fractions one weekapart using parallel opposedfields were studied. In addition to
the conventional anteroposterior simulator film, a lateral simulator film was also
taken to determine patient separations and the depth ofthe spinal cord. The
central axis, superior and inferior separations were recordedby a radiographer.
The maximum spinal corddose was calculated without lungcorrection fora6OCo
unit and6MV and 8MV linear accelerators. The maximum spinal cord doses were
used to calculate the LQED2 using an alpha/beta ratio of2Gy.2
Results The mean patient seperations were 19cm (range 17-23.5cm) at the
central axis,18.5cm at the superior fieldborder (range 14-21.5cm) and 21.5cm at
the inferior field border (range 18.5-25.5cm). The mean maximum corddoses
were 5.1% (range 2.2%/o-7.5%), 7.3% (range 4.10/6-l 1.6%) and 10.3% (range
3.1/o-16. 1%) higherthan the prescibed midplane dose for 8MV, 6MV and
6OCobalt respectively. An LQED2 ofgreater than 48Gy was found in 14 (83%) of
patients using6OCo, 15 (100%) patients using 6MV and 10 (67%) ofpatients
using 8MVrespectively.
Conclusions This small study demonstrates greatervariations in the maximum
corddose than expected. Maximum spinal cord doses are dependent on separation
and machine energy andclinicians need to take account ofthese factors when
deciding whether steps shouldbe taken to reduce the maximum dose to the spinal
cord.
' Medical Research Council Working Party. Br J Cancer 1991;63:265-270
2 McBeth et al Clinical Oncology 1996;8:176-181
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A PHASE 11 OF CISPLATIN (CDDP) IFOSFAMIDE (IFM) AND
INCREASING DOSAGE OF NAVELBINE (NVB) IN
UNRESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC)
P.J. Souquet1, P.Foumel2 - IService de Pneumologie CH, Pierre Benite Lyon-France, 2
Service de Pneumologie CH St Etienne-France.
CDDP, IFM and NVB are the most active drugs in NSCLC, as single agent. NVB
has already shown an increased survival rate in randomised trials. In particular,
one of such trial showed the combination of NVB and cisplatin to result in
statistically superior survival compared with standard therapy (JCO 1994), This
was recently confinrned by the SWOG study comparing NVB+CDDP vs CDDP
(ASCO 1966). Preliminary results with NVB+CDDP+IFM are very encouraging.
Based on this data, since 12/92 to 02/94 a clinical trial was performed in
patients(pts) with unresectable stage III (IIIA N2, IIIB) NSCLC treated with 3
different schedules Group A CDDP (75mg/M2 D1)+IFM (3g/m2 D1)+NVB
(25mg/mi on Dl); GrouR B CDDP (75mg/mi D1)+IFM (3g/m2 D1)+NVB
(25mg/m' on DI & 8); GrouR C: CDDP (75mg/m2 D1)+IFM (3g/m2 Dl)+NVB
(25mg/mi on days 1 & 15 and 12.5mg/mi on day 8) every 21 days. The purpose
was to assess the response rate (RR), survival and tolerance. A first assessment,
according to WHO criteria was done after 3 cycles. After this, stage III patients
received standard radiotherapy (6OGy over 6 weeks) and responding stage IV pts
received 3 cycles more.
85 pts were included (A: 35 pts; B: 28 pts; C24 pts): median age 59 y. (range 36-
73) males 74 pts, stage III 37 pts; stage IV 48 pts. 32 pts suffered from
adencarcinoma, 37 from squamous cell and 16 fromundifferentiated cell.
Dose intensity (according to Hryniuk method) was the same for the 3 groups
concerning CDDP and IFM. For NVB dose density was 8.1mg/m/w,
14.7mg/m2/w and 16.9mg/m2/w for A,B,C groups respectively. Haematological
toxicity was predominantly observed, mainly in the group B.
5 pts achieved complete response (CR), 36 pts partial response (PR) after 3 cycles
but 14 CR and 17 PR at the end oftreatment. The overall median survival( MS) 40
ws. The RR observed by group was 31.5% (30 ws MS), 44.5% (40 ws MS), 66.6%
((55 ws MS) for group A,B and C respectevely.
This study confirms that increased dose intensity with. NVB is feasible and
improves response rate and survival withouthaematological toxicity raise.
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NEOADJUVANT CHEMOTHERAPY WITH NAVELBINE P060 Vv (NVB) PLUS CISPLATIN (C) IN STAGE IIIB IN NON-
SMALL CELL LUNG CANCER (NSCLC): A PHASE II TRIAL
Cigolari S.1, Curcio C.2, Massimo M.3, SessaR.3, Vasta M.2, Maiorino A.3
Universita Federico 11, 2Hospital Ascalesi, 3Hospital Monaldi (Napoli, Italy).
NVB+C has already proven to be one ofthe most effective regimen in NSCLC in
terms of survival for patients (pts) with unresectable disease (Le Chevalier, JCO,
1994). Based on these results we planned to treat pts with stage IIIB NSCLC < 75
years(y) old, in order to determine response rate (RR) and operability of locally
advanced disease.
Patient's characteristics: between Apr.1996 and Nov.1996, 30 pts were accrued:
28 of them were evaluable (1 too early, 1 lost to follw-up); median PS 1; median
age 61 y (38 - 75).
Treatment: NVB 30 mg/M2 on Dl and D8 and C 120 mg/mi on Dl in a 21-day
schedule for 3 cycles before restaging. G-CSF was permitted in case of severe
neutropenia.
Results: A total of 81 cycles have been administered with mainly myelotoxicity:
anemia grade(G) 3: 13%, leucopenia G3: 16%; no thrombocytopenia. Clinical
toxicity was mainly nausea and vomiting G3 in 66%.
The efficacy after 3 cycles was: 16/28 (57%) partial response, 8 of them were
resected, all responders were confirmed by an independant external expert group;
6/28 no change and 6/28 progressive disease.
Conclusions: This NVB+C as a neoadjuvant schema showed a high RR (57%),
resulted in patients being able to proceed to resection and will be tried in a Phase
III clinical study in order to study its possible effects on survival.
AN OVERVIEW OF3 PHASE II TRIALS OFNAVELBINE(NVB), AND P062 FRACTIONATED DOSES OF CISPLATIN (CDDP) IN THE MANAGEMENT OF
ADVANCED NON-SMALL CELLLUNGCANCER (NSCLC)
M.Pawlickil, J. Rodrigues2, D. Firat3, F. LeBras4 & FM. Delgado4-
I- Onc. Cent. Krakow-Poland; 2-ELAN-Brazil; 3-Ankara Univ. Turkey; 4- I.R.P.F., France.
AIM: The combination of NVB and CDDP has shown statistically superior
survival compared with standard therapy (JCO 1994, ASCO 1996). 3 phase II
studies were conducted to assess a new schedule ofthis combination which can be
given on an out-patient basis: NVB 25 mg/m2 (1 trial 30 mg/m2) on day I & 5 and
CDDP 20 mg/mi daily over 5 days (DI-5) every 21 days, (maximum 6 cycles).
Results: Between 7/94 and 2/96, 127 (pts) were included: median age 60 (34-75).
112 (88%) males; PS 0, 1 and 2, 16%, 55% and 27% respectively. squamous cell -
56% ,adenocarcinoma -36% and large cell -8%; 12% stage IILA, 36% stage IIIB
and 49% stage IV and 3% unknown (metastatic). 471 courses were administered
(median 4, range 1-8). WHO grade (G) 3-4 neutropenia -12%; G34 infection
episodes 1.4% ofcourses. G 3 nausea/vomiting: 18% (5.4% ofcourses). Only 4%
ofpts developed WHO grade 3 constipation and grade 3-4 peripheral neuropathy
was observed in 9% ofpts (2.4% G 4). G3 alopecia -12%. The overall response
rates observed in Brazilian, Polish and Turkish studies are 46%, 47%
(N 30 mg/mi) and 29% respectively; median TTP: 7.4 months and median survival
is: 9.2 months Conclusion. These results confirm that NVB + CDDP in
combination have constant and reproducible high antitumour activity in NSCLC.
This new schedule seems well suited for use in the out patient management of
NSCLC.
P061 CHEMOTHERAPY WITHVINORELBINE (NAVELBINE:
NVB) + CARBOPLATIN IN ADVANCED NON-SMALL
CELL LUNG CANCER (NSCLC)
B. Parentel, F. Barata2, J. Moura e Sal, R. Pato2, L. Hortal,
J. Seadal - ICentro Hospitalar Vila Nova de Gaia, 2Centro Hosp. de Coimbra - Portugal
Between Jan. 1995 and May 1996, 75 patients (pts) (56 and 19 from Vila Nova de
Gaia Hospital and Coimbra Hospital respectively) with advanced NSCLC were
treated with NVB (30 mg/mi) on days 1 and 8 and Carboplatin (300 mg/m2) on day
1, every 3 weeks (w). Pts were evaluated after 3 cycles and the treatment was
continued for a further 3 cycles in case oftumor response.
Patient's characteristics: sex F/M: 11/64, median age 59 y (27-73), PS 1: 75%, PS
2: 25%; histology: epidermoid: 52%; adenocarcinoma: 44%; others: 4%. Stage IILA,
HIB and IV: 1.4%, 69.3%, 29.3% respectively.
Results: The overall response rate was 45.3% with a median duration of 31 w; the
median overall survival was 34 w; the median survival ofresponders was 43.5 w.
Toxicity: 332 cycles were administred and the limiting toxicity was mainly
myelosupression: WHO Grade(G) 3 anemia: 4%; G3-4 neutropenia: 23%; G3-4
dtrombocytopenia: 4%; acceptable non haematological toxicity: local reaction: 20%
and no significative alopecia were observed.
Conclusions: This study confirms that this combination achieves a high response
rate, good median survival with acceptable tolerance. This combination should be
recommended for the treatment ofpts with NSCLC on an outpatientbasis.
P063 THYROGLOBULIN ANTIBODIES IN
DIFFERENTIATED THYROID CANCER.
P. Hjiyiannakis, J. Mundy, C. Harmer, Thyroid Unit, Royal
Marsden NHS Trust, Downs Road, Sutton, Surrey SM2 5PT UK
INTRODUCTION A retrospective review of patients with
differentiated thyroid cancer between 1984-1996, at The Royal
Marsden Hospital, identified 40 patients with serum
Thyroglobulin Antibodies (TgAb). These can interfere with the
immunoradiometric assay (IRMA) for Thyroglobulin (Tg) used
at this hospital, with a resultant underestimation of the Tg
levels. Median follow up from diagnosis was 26 months
(range 3-401 months); median age at diagnosis was 50 years.
RESULTS Patients were assigned to one of two groups: group
1 with TgAb>1/100 (n=28) and group 2 with TgAb<1/100
(n=12). Fourteen patients recurred: 12 in group 1 and 2 in
group 2. Sites of recurrence were: neck (n=10), lung (n=5), bone
(n=4), brain (n=2). None of the patients in group 1 showed an
elevated Tg with recurrence. One patient in group 2, in whom
the TgAb did not interfere with Tg assay, showed an
appropriate Tg response with recurrence. Eight patients in
group 1 had TgAb development apparently in response to
tumour recurrence. Seven of these patients have died, with a
median overall survival of 26 months from diagnosis. TgAb
presence did not influence overall survival of the whole group
or overall survival of patients with papillary carcinoma (n=34).
CONCLUSION We recommend that laboratories should
routinely report the presence of TgAb, with a caution
indicating the direction of possible error (which depends on
the assay used). Development of TgAb can indicate tumour
recurrence, which carries a poor prognosis. In TgAb positive
patients serial monitoring may offer additional, clinically
useful, information.